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Abstract
We conducted a systematic review and meta-analysis to assess the association of MTX
with cardiovascular morbidity, cardiovascular mortality and all-cause mortality in patients
with autoimmune disease. Our primary outcome was incident cardiovascular events. After
screening 13,479 citations, we identified a total of 30 eligible studies. We synthesized
adjusted risk estimates using a random effects model. MTX was significantly associated
with a 25% reduction in cardiovascular events (pooled RR: 0.75, 95% CI: 0.65, 0.86, I2:
11%), a 55% reduction in cardiovascular mortality (0.45, 95% CI: 0.26, 0.80, I2: 33%)
and a 40% reduction in all-cause mortality (0.60, 95% CI: 0.48, 0.76, I2: 45%). Low-dose
MTX was associated with a stronger effect size for reducing cardiovascular events
compared to high-dose MTX (0.61, 95% CI: 0.51, 0.74 versus 0.88, 95% CI: 0.78, 0.99).
We concluded a significant associative reduction in cardiovascular events with the use of
low-dose MTX in patients with autoimmune disease.
Keywords: Methotrexate, autoimmune disease, cardiovascular events, mortality,
rheumatoid arthritis, psoriasis, systematic review, meta-analysis
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Chapter 1: Introduction

1. Overview
The objective of this thesis is to quantify the association of methotrexate (a commonly
used therapy for a variety of autoimmune conditions) with cardiovascular morbidity,
cardiovascular mortality and all-cause mortality in patients with autoimmune disease. We
conducted a systematic review and meta-analysis of trials and observational studies
meeting restricted eligibility criteria. We included autoimmune diseases in which
methotrexate has been used as one of the treatment options. We used the NewcastleOttawa scale for quality assessment of observational studies, and the Cochrane risk of
bias instrument to appraise the quality of randomized trials.1,2
2. Scope of the problem
Cardiovascular diseases such as coronary artery disease, peripheral arterial disease,
stroke, and venous thromboembolism are the leading cause of morbidity and mortality in
developed as well as developing countries, accounting for 30% of all deaths worldwide in
2008.3 Of these deaths, an estimated 42% of deaths were a result of coronary artery
disease and 36% of deaths were attributed to stroke.4 Cardiovascular disease has no
geographic, socioeconomic or sex boundaries. According to World Health Organization
(WHO) data published in 2011, 80% of deaths among young individuals in low and
middle income countries were due to cardiovascular disease.3 Moreover, costs of treating
cardiovascular disease are among the highest for chronic diseases. These costs constituted
17% of all annual medical expenditures in the United States, 12% in the European Union
and 17% in the United Kingdom.5,6 In Canada, while the death rate from cardiovascular
disease declined in the last decade, mortality from cardiovascular disease remained the
second leading cause of death after cancer (and 25.2% of all deaths).7 Despite improved
management and optimal patient care, cardiovascular disease remains the largest single
contributor to mortality worldwide. WHO estimates annual deaths due to cardiovascular
disease to reach more than 23 million by 2030.3
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The global burden of cardiovascular disease will continue to increase due to multidimensional effects of cardiovascular risk factors and population aging. Cardiovascular
disease is not only caused by major individual cardiovascular risk factors but also by
other contributing conditions that alter these risk factors, directly or indirectly. Some
novel risk factors for cardiovascular disease include high levels of C-reactive protein,
lipoprotein (a), homocysteine, LDL-c particle size and fibrinogen.8-10 Various chronic
medical conditions such as end-stage renal disease, chronic inflammatory connective
tissue diseases, and human immunodeficiency virus infection are also considered to be
risk factors for cardiovascular disease.10 In addition, disturbances in tissue plasminogen
activator (tPA) levels and low serum testosterone are known to contribute to
cardiovascular disease.11,12 Other situations including hysterectomy before the age of 50
and psychosocial conditions such as mental stress, depression and poor sleep quality are
also risk factors for cardiovascular disease.10
Some of the above risk factors such as hypertension, diabetes mellitus, dyslipidemia,
smoking, obesity and physical activity can be modified and controlled while others
cannot. Declining trends in cardiovascular mortality over the past few decades have been
observed due to increased awareness, improved management of modifiable risk factors
and medical treatment of patients with cardiovascular disease.13,14 A number of health
promotion and prevention programs have also played an important role. Conversely, due
to increased prevalence of physical inactivity, obesity, diabetes, high calorie consumption
and other risk factors, global morbidity and mortality from cardiovascular disease remains
high. Considering the global burden of cardiovascular disease and the health
consequences for individual patients, there is a significant need to address other
preventive measures for cardiovascular disease that are associated with novel and nontraditional risk factors.
Until now, scant attention has been paid to addressing some of these novel risk factors
that may have importance in ameliorating cardiovascular disease. Autoimmune diseases
are one of these risk factors. The enhanced risk of cardiovascular disease in major
autoimmune disease is a significant clinical problem.
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Autoimmune diseases represent a variety of disease manifestations and jointly they affect
5-10% of the population in developed countries.15,16 Disease activity and severity are
associated with high mortality in patients with autoimmune disease; yet with the
availability of better therapies, the lifespan of these patients has improved. Hence in part
due to improved survival, the long-term consequences of these diseases such as coronary
artery disease and stroke are increasingly manifest. Autoimmune diseases cause chronic
inflammation and immune dysregulation, which lead to increased autoantibody
production, dyslipidemia, platelet dysfunction and vascular pathology, which are
consequently responsible for atherosclerosis.17,18,19 Thus, premature atherosclerosis is
more frequent in patients with systemic autoimmune conditions.
A broader concept of therapy targeting inflammation is needed to reduce morbidity and
mortality due to cardiovascular as well as autoimmune disease. Different
immunotherapeutic agents are in use to treat various autoimmune conditions. The effect
of these therapeutic agents on the cardiovascular system and mortality remains a vital
issue. One routinely used agent is methotrexate (MTX).
3. Relationship of autoimmune disease with cardiovascular disease,
cardiovascular mortality and all-cause mortality
3.1 Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease affecting multiple
joints that leads to joint destruction, deformity, loss of function and reduced life
expectancy. Due to the inflammatory nature of the disease, RA patients are more prone to
develop cardiovascular disease than the general population.20,21 Several studies also
identified a higher cardiovascular and all-cause mortality in RA patients compared to the
general population.22 In a cohort study, Young et al identified a standardized mortality
ratio (SMR) of 1.27 (95% CI: 1.04, 1.46) in RA patients compared to the general
population in the United Kingdom.22 In another population based cohort study, Turesson
et al reported an age and sex adjusted standardized morbidity ratio of 1.61 (95% CI: 1.21,
2.10) for first ever acute myocardial infarction or stroke in RA patients compared to the
Malmo, Sweden general population.23 Maradit-Kremers et al found a hazard ratio (HR) of
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2.41 (95% CI: 1.00, 5.81) for cardiovascular death in RA patients with concomitant
vasculitis compared to RA patients without vasculitis.24
3.2 Psoriasis
Psoriasis is a chronic inflammatory autoimmune disease of skin characterized by red
elevated patches and flaking silvery scales. Severe psoriasis appears to be associated with
an increased risk of cardiovascular morbidity and mortality. A study conducted by
Gelfand et al reported an incidence rate of 5.13 (95% CI: 4.22, 6.17) per 1000 person
years for myocardial infarction in patients with psoriasis in contrast with 3.58 (95% CI:
3.52, 3.65) per 1000 person years in the control group.25 In a recently published metaanalysis, Horreau et al reported an odds ratio of 1.19 (95% CI: 1.14, 1.24) in crosssectional studies, 1.20 (95% CI: 1.13, 1.27) in cohort studies, and 1.84 (95% CI: 1.09,
3.09) in case-control studies for the risk of coronary artery disease in psoriasis patients
compared to patients without psoriasis.26 For mortality, Abuabara et al conducted a
population-based cohort study and found a higher overall death rate (26, 95% CI: 23, 29
per 1000 patient-years) in psoriasis patients compared to patients without psoriasis (18,
95% CI: 17, 19 per 1000 patient-years).27
3.3 Psoriatic Arthritis
Psoriatic arthritis is an inflammatory arthritis associated with psoriasis. Like psoriasis and
RA, psoriatic arthritis also carries a high risk of cardiovascular morbidity and mortality.
A cohort study from Toronto, Ontario identified high cardiovascular and all-cause
mortality in patients with psoriatic arthritis compared to the general population, with a
standardized mortality ratio of 1.62 (95% CI: 1.21, 2.12).28
3.4 Systemic sclerosis
Systemic sclerosis is a multisystem autoimmune disease characterized by abnormal
growth of connective tissue and fibrosis. Barnes and Mayes found higher mortality in
systemic sclerosis patients compared to the general population, with a standard mortality
ratio of 1.46 (95% CI: 1.28, 1.69).29 Additionally, they noted that 55% of deaths in
systemic sclerosis patients were directly related to the disease itself and 14% of deaths
were due to systemic sclerosis-related myocardial disease. A retrospective analysis
carried out by Man et al from the General Practitioner database in the United Kingdom
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reported a two-fold increase in the risk of myocardial infarction and stroke in systemic
sclerosis patients compared to those without systemic sclerosis.30
3.5 Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of various
manifestations affecting skin, joints, kidney, brain, and other organs. Petri et al observed
that the prevalence rate of cardiovascular disease ranged from 6 to 10% in individuals
with SLE.31 The mortality rate in SLE is 2-5 times higher than that of the general
population.32 Yurkovich et al demonstrated a three-fold increased risk of death in SLE
patients compared to the general population, with a pooled standardized mortality ratio of
2.98 (95% CI: 2.32, 3.83).33 They also showed a standardized mortality ratio of 2.72
(95% CI: 1.83, 4.04) due to cardiovascular disease in SLE patients compared with the
general population.
3.6 Dermatomyositis and polymyositis
Dermatomyositis (DM) is a connective tissue disorder characterized by inflammation of
muscle and skin. As a systemic disorder, it may affect the joints, esophagus, lungs, and
heart. Polymyositis causes muscle inflammation and diffuse weakness of both sides of the
body, mainly affects proximal muscles. In Finland, Airio et al carried out a retrospective
analysis of dermatomyositis and polymyositis patients from a hospital database.34 They
showed a standardized mortality ratio of 2.92 (95% CI: 2.82, 3.44) in these patients. In
this cohort, the main cause of mortality was cardiovascular disease (in 31% of
dermatomyositis patients).
3.7 Multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory, debilitating disease of the nervous
system, resulting in various signs and symptoms. A higher mortality rate is observed in
patients with multiple sclerosis compared to the general population.35 A recently
published population-based cohort study observed a 3.5-fold all-cause mortality rate in
multiple sclerosis patients compared to the reference population with a hazard ratio of
3.51 (95% CI: 2.63, 4.69).36 In the same study, the hazard ratio due to cardiovascular
death in multiple sclerosis patients was found to be 2.42 (95% CI: 1.47, 3.97).
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3.8 Sjogren’s syndrome
Sjogren’s syndrome is an inflammatory disease of the immune system that can affect
different parts of body but most commonly affects the eye and salivary glands. Previous
studies have identified evidence of metabolic abnormalities in primary Sjogren’s
syndrome that may increase the risk of stroke and cardiovascular disease in these
patients.37 However, Chiang et al reported an adjusted hazard ratio of 0.84 (95% CI: 0.62,
1.12) for ischemic stroke in primary Sjogren’s patients compared to a non-Sjogren’s
control group.38 There was no difference in the survival between Sjogren’s syndrome and
the healthy population. Theander et al and Nannini et al reported non-significant
differences in mortality between patients with Sjogren’s syndrome and the general
population.39,40
3.9 Bullous pemphigoid
Bullous pemphigoid (BP) is a chronic, autoimmune, subepidermal, blistering disease of
skin that often affects the lower abdomen, upper thighs or armpits. In Langan et al,
patients with bullous pemphigoid had more than twice the all-cause mortality than that of
the control group with an adjusted hazard ratio of 2.3 (95% CI: 2.0, 2.7).41 In Taiwan,
Yang et al carried out an analysis from Taiwan’s National Insurance Research Database
(NHIRD) and determined an adjusted hazard ratio of 2.37 (95% CI: 1.78, 3.15) for stroke
in patients with bullous pemphigoid.42
3.10

Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD) is a group of autoimmune inflammatory conditions
that affect the digestive system. Crohn’s disease (CD) and ulcerative colitis (UC) are the
major types of IBD. A study conducted in Canada by Bernstein et al reported an increased
risk of ischemic heart disease in IBD patients (both in CD and UC) with an incidence risk
ratio of 1.26 (95% CI: 1.11, 1.44).43 In a cohort study, Jess et al found intermediate and
long-term mortality rates increased by 10% (in relative terms) among patients with UC
and 50% among patients with CD when compared with the general population.44 The
authors also reported a hazard ratio of 1.20 (95% CI: 1.14, 1.26) in UC and 1.39 (95% CI:
1.28, 1.51) in CD for death due to cardiovascular disease.44 Cart et al reported similar

7

results in a study from the United Kingdom with a hazard ratio of 1.54 (95% CI: 1.44,
1.65) for deaths among IBD patients after adjusting for age, sex and smoking status.45
3.11

Transverse Myelitis

Transverse myelitis is an inflammatory disease of the spinal cord of varied etiology
resulting from loss of spinal cord functions over several hours to weeks. Apart from
infections and vaccinations for infectious diseases, causes of transverse myelitis also
include several autoimmune conditions such as systemic lupus erythematosus, Sjogren’s
syndrome, Behcet’s disease, antiphospholipid syndrome, multiple sclerosis, neuromyelitis
optica and other rheumatic diseases.46 To the best of our knowledge, no data on
cardiovascular risk exist for transverse myelitis.
3.12

Myasthenia Gravis

Myasthenia Gravis (MG) is a chronic autoimmune disease of neuromuscular system
characterized by weakness and fatigue of skeletal muscle. Evidence supporting a
relationship between myasthenia gravis and cardiovascular disease is limited. However, a
study published in 1984 by Hofstad et al observed a relationship of heart disease with
myasthenia gravis.47 The authors in this study observed that 16% of myasthenia gravis
patients exhibited signs of heart disease. In contrast, Owe et al examined 1,992,342
deaths from the Norwegian Cause of Death Register from 1951 to 2001 and determined
significantly lower cardiac disease in myasthenia gravis patients compared to the controls
in the age group 50-69 (19.4% in myasthenia gravis patients versus 52.0% in controls for
men, p=0.001, and 14.6% versus 29.6% for women, p=0.036).48
3.13

Wegener’s Granulomatosis

Wegener’s granulomatosis is a chronic inflammatory disease of small and medium size
vessels characterized by granuloma formation that affects many organs and requires long
term immunosuppression therapy. It is also known as granulomatosis with
polyangiitis (GPA). It is a rare disease with varied geographic distribution. Watts et al
noted an increasing trend in prevalence in the United Kingdom with a prevalence rate of
62.9 per million in December 1997 and 148 per million at the end of 2010.49
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3.14

Microscopic Polyangiitis

Microscopic polyangiitis (MPA) is a chronic autoimmune vasculitis characterized by
necrosis of small size blood vessels without granulomatous inflammation. In contrast to
Wegener’s granulomatosis, it usually affects the lower respiratory tract and is associated
with anti-neutrophil cytoplasmic autoantibody (ANCA) directed against myeloperoxidase
(MPO). Watts et al reported a mean annual incidence of 5.9 per million population (95%
CI: 4.4, 7.5) for MPA in the United Kingdom during the period of 1988-2010.49 They also
noted an increasing trend in prevalence for GPA and MPA in the United Kingdom.
3.15

Eosinophilic Granulomatosis with Polyangiitis

Eosinophilic granulomatosis with polyangiitis (EGPA) is one of three ANCA-associated
vasculitides, predominantly affecting small size blood vessels. It is also known as a
Churg-Strauss Syndrome (CSS).
GPA, MPA and EGPA are also known as ANPA-associated vasculitis. In these patients,
an increased mortality due to cardiovascular disease is well-documented. The relative risk
for coronary heart disease and stroke in ANCA-associated vasculitis is 2 to 4-fold higher
than that in control patients.50 ANCA-related vasculitis patients may experience
accelerated atherosclerosis.50
3.16

Takayasu’s Arteritis

Takayasu’s arteritis (TA) is a rare, systemic inflammatory vasculitis of large vessels
leading to abnormal stenosis or aneurysm of vessels. Affected patients are more prone to
accelerated atherosclerosis. About 10-30% and 10-20% of Takayasu’s arteritis patients
experience coronary artery disease and stroke respectively due to hemodynamic
compromise in large artery stenosis and thromboembolism.50

Overall, autoimmune disease are associated with increased risk of cardiovascular events,
cardiovascular mortality and all-cause mortality worldwide.51-54 Autoimmune disease is
one of the top ten causes of death and mostly affects women.51
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4. Mechanisms of cardiovascular disease in autoimmune disease
Development of cardiovascular disease relies on the contributions of both genetic and
environmental risk factors. Evidence supports the association of atherosclerosis with
chronic inflammation. Shoenfeld et al note the absence of traditional cardiovascular risk
factors in approximately 40% of patients with myocardial infarction or stroke and suggest
an involvement of inflammatory and immune mechanisms in the rapid development of
atherosclerosis.55 They also identified the participation of several autoantigens and
autoantibodies in the process of atherosclerosis.

Figure 1. Components of immune system in the process of atherosclerosis.
(Source: Sherer and Shoenfeld)56. Reproduced with permission.
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4.1 Atherosclerosis in autoimmune disease
Atherosclerotic plaque is characterized by accumulation of lipid particles and immune
cells in the artery’s subendothelial region. Components of the immune system involved in
the process of atherosclerosis include macrophages, T-cells, autoantibodies, autoantigens,
LDL particles, cytokines including tumor-necrosis factor (TNF), interleukin 1 (IL-1), IL2, IL-6, IL-8, IL-10, IL-12, interferon-γ and platelet-derived growth factor (Figure 1).56
In RA, several factors accelerate the process of atherosclerosis, including lifestyle,
modifiable risk factors, lipid dysregulation, chronic inflammation, immune dysregulation,
functional abnormalities of the vascular endothelium, and expansion of CD4+CD28cells.17 In SLE, high prevalence of modifiable cardiovascular risk factors, increased
inflammatory markers, coronary artery calcification and increased levels of oxidised LDL
(oxLDL) are associated with accelerated atherosclerosis.56
The exact mechanism of atherosclerosis is not yet clear in systemic sclerosis. However,
based on available evidence, it can be inferred that atherosclerosis and vascular disease in
systemic sclerosis is caused by several factors such as impaired coronary
microcirculation, endothelial injury, intimal thickening, destruction of the internal elastic
lamina, transmural lymphocytic cellular infiltration and increased intimal-medial
thickness of the major vessels.17
GPA, MPA and ECGA are types of primary systemic vasculitides (PSVs) which may
trigger atherosclerosis through inflammation and immune reaction. In these diseases, due
to a vascular bed lesion, inflammation and in-situ immune reactions activate the
endothelial cells in the vessel’s intima. This further exposes adhesive molecules to secrete
cytokines, chemokines, growth factors and metalloproteinases at the site resulting in rapid
atherosclerosis.17 Several factors such as increased intimal-medial thickness, C-reactive
protein, matrix metalloproteinases, several pathological autoantibodies and oxidised LDL
are responsible for the accelerated atherosclerotic process in the primary systemic
vasculitides.17
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5. Methotrexate
Methotrexate (MTX) is a disease-modifying anti-rheumatic drug (DMARD) which
reduces inflammation in autoimmune disease by suppressing the immune system. While
originally designed to treat cancer as a chemotherapeutic agent, it has proven safe and
well-tolerated in several autoimmune conditions when used in low doses. It is commonly
used as part of the standard of care in first, second or third-line therapy in various
autoimmune diseases. Its safety and efficacy have been proved in placebo-controlled
trials as well as in active comparator trials using other disease modifying anti-rheumatic
drugs.57,58
Methotrexate’s potential cardioprotective effects may operate through reducing systemic
inflammation and by a direct effect on the cellular mechanisms responsible for
atherosclerosis. Cutolo et al reviewed different anti-rheumatic and anti-inflammatory
mechanisms of MTX.59 In their review, they noted that low-dose methotrexate exerts both
anti-proliferative and anti-inflammatory effects through different pathophysiological
mechanisms. Describing the first mechanism, MTX increases extracellular adenosine,
which interact with specific cell surface receptors (A2A and A3) and inhibits IL-8, IL-6,
and leukotriene B4. Secondly, MTX reduces the production of pro-inflammatory
monocytic and macrophagic cytokines, including IL-1, IL-6, and TNF-α. Furthermore,
MTX increases the gene expression of anti-inflammatory Th-2 cytokines (IL-4, IL-10)
and decreases the gene expression of pro-inflammatory Th-1 cytokines (IL-2, IFNγ).59
Coomes et al also describe mechanisms by which MTX reduces atherosclerosis.60
According to their review, MTX activates A2A and A3 adenosine receptors by releasing
adenosine, which consequently up-regulates expression of ABCA1 and 27-hydroxylase.
Steps and details of these mechanisms are described in the following Figure 2.
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Figure 2. Anti-atherogenic mechanisms of MTX
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6. Study rationale
To date, no clinical trial has been conducted addressing the direct association of MTX use
and cardiovascular morbidity and mortality in patients with rheumatic and autoimmune
disease. Currently, the Cardiovascular Inflammation Reduction Trial (CIRT) is ongoing
and recruiting patients to investigate the effect of low-dose MTX on the rate of recurrent
cardiovascular events in patients with prior myocardial infarction plus either type 2
diabetes or the metabolic syndrome.61,62 However, CIRT is focused on an established
secondary prevention population while excluding patients with autoimmune disease who
are also at risk.
Observational studies including cross-sectional, case-control and cohort studies have
addressed the association between the effect of methotrexate and cardiovascular
morbidity and mortality in patients with RA, psoriasis, SLE, and psoriatic arthritis.63-71
These studies are observational and thus not free from the limitations and weaknesses
related to their nonrandomized design. Such studies are subject to two major types of
bias. The first is ‘confounding by indication’, whereby in real world clinical practice,
sicker patients with a greater indication for treatment would be more likely to get
methotrexate than less sick patients. Additionally, these patients may have high
inflammation, which leads to increased risk of cardiovascular disease. The second type of
bias is ‘physician selection bias’, where there is a likelihood of selecting methotrexate
over other DMARDs in practice, particularly when deciding systemic therapy for
psoriasis patients. A non-randomized comparison due to these biases either
underestimates or overestimates the effect of methotrexate in reducing cardiovascular
disease. To generate a scientifically relevant evidence and understand the relationship of
MTX with CVD, we conducted this systematic review, focused on the good quality
studies, and tested the results for consistency across various disease endpoints.
Several recent reviews have studied the relationship between MTX and cardiovascular
morbidity.60,72-74 Micha et al reported an overall 21% and 18% reduction in
cardiovascular disease and myocardial infarction respectively, in patients treated with
MTX compared to those treated with other anti-rheumatic agents.72 The pooled estimate
from this review did not measure an independent effect of methotrexate since the
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comparison group consisted of active treatment. Moreover, this meta-analysis assessed
only ‘hard’ cardiovascular events and not ‘softer’ events such as heart failure. The
authors did not assess the association of MTX with mortality. Finally, this meta-analysis
included studies published up to June 2010 only. We are expecting to add more studies
on the topic which were published after 2010.63,70,75
Another systematic review published by Westlake et al in 2010 also found a
cardioprotective effect of MTX, but included only RA patients.73 As well, this review
was limited to cardiovascular disease and did not include mortality as a corollary
outcome. Finally, the authors did not perform a meta-analysis to quantify the overall
association between MTX exposure and cardiovascular disease.
Marks and Edwards studied pathogenesis and risk factors for cardiovascular disease in
RA patients.74 Coomes et al described an overview of the mechanism by which MTX
interferes with cholesterol homeostasis and reduces atherogenesis in inflammatory
conditions.60 These narrative reviews used surrogate markers and established biological
plausibility for the protective association between MTX and cardiovascular disease.

7. Research questions
7.1 Primary question
Is methotrexate associated with a lower risk of cardiovascular events in patients with
autoimmune disease?
Hypothesis: We hypothesize that treatment with methotrexate is associated with a lower
risk of cardiovascular events in patients with autoimmune disease, even after adjustment
for potential confounders.

7.2 Secondary question
Is methotrexate associated with a lower risk of cardiovascular mortality, all-cause
mortality, and other cardiovascular disease endpoints such as coronary events and stroke?
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Hypothesis: We hypothesize that methotrexate is associated with a lower risk of
cardiovascular mortality, all-cause mortality, and cardiovascular disease endpoints in
patients with autoimmune disease.
7.3 Exploratory question (dose-response analysis)
Does the association of methotrexate with cardiovascular events vary by different doses
(high or low methotrexate doses)?
Hypothesis: We hypothesize that treatment with high-dose methotrexate is associated
with a lower risk of cardiovascular events than treatment with low-dose methotrexate.
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Chapter 2: Methods
1. Overview
Using the framework of a systematic review, we quantified the associative risk of MTX
for cardiovascular events, cardiovascular mortality and all-cause mortality in patients
with autoimmune disease. This review was conducted in accord with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (see
Appendix A for PRISMA Checklist).76
In terms of study designs, we evaluated cohort studies, case-control studies and
randomized controlled trials. We selected cardiovascular events as the primary outcome,
given its biological relevance to MTX’s mechanism of action. We included autoimmune
diseases for which MTX is used as a treatment agent in first, second or third line therapy.
We evaluated the association of MTX with events according to a number of parameters
including type of autoimmune disease, demographic factors, dose-response, observation
period and other potential sources of heterogeneity. We registered our study protocol with
the International Prospective Register of Systematic Reviews.
2. Criteria for considering studies
To identify relevant studies, we prespecified the following criteria for types of
autoimmune disease, treatment and control groups, and outcomes.
2.1 Study patients
The autoimmune diseases included in this systematic review are rheumatoid arthritis,
psoriasis, psoriatic arthritis, dermatomyositis, polymyositis, systemic lupus
erythematosus, multiple sclerosis, Sjogren’s syndrome, bullous pemphigoid, Crohn’s
disease, ulcerative colitis, transverse myelitis, systemic sclerosis, myasthenia gravis,
Wegener’s granulomatosis, microscopic polyangiitis, eosinophilic granulomatosis with
polyangiitis and Takayasu’s arteritis. We prepared this list of eligible autoimmune
diseases by comprehensively searching the online reference “UpToDate”, and by
reviewing clinical textbooks of rheumatology.77 Two investigators, a clinical
pharmacologist and a practicing rheumatologist (specializing in vasculitis), reviewed this
list and finalized the diseases to be included in this meta-analysis. We included
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autoimmune diseases for which MTX is used as a treatment agent in first, second or third
line therapy.
2.2 Intervention and comparison group
The included study must compare MTX users to non-users (either placebo or a no-MTX
comparator group).
2.3 Outcomes measured
We included studies that reported any of the following outcomes: cardiovascular events
(including composite cardiovascular endpoints), fatal or non-fatal myocardial infarction,
coronary artery disease, acute coronary syndrome, heart failure, cardiac arrest, sudden
cardiac death, hospitalization due to cardiovascular events, stroke, cardiovascular
mortality and all-cause mortality. We defined all our outcomes using International
Classification of Diseases version 10 (ICD-10) criteria.78
a. Cardiovascular events (ICD-10: I00-I99): In this category, we considered composite
cardiovascular endpoints which include any of the following events: fatal or non-fatal
myocardial infarction, angina pectoris, coronary interventions such as coronary
bypass grafting or percutaneous coronary intervention, acute heart failure, peripheral
arterial disease, vascular surgery, ischemic stroke, transient ischemic attack, and
carotid endarterectomy.
b. Coronary events (ICD-10: I20-I25): This includes angina pectoris, myocardial
infarction and complications associated with myocardial infarction. We also included
any hospitalization or death due to coronary events in this group.
c. Myocardial Infarction (ICD-10: I21-I23): This includes fatal or non-fatal myocardial
infarction along with acute (ICD-10: I21) and subsequent (ICD-10: I22) myocardial
infarction and its complications (ICD-10: I23).
d. Acute Coronary Syndrome ICD-10: I24.9): This refers to conditions attributed to
acute obstruction of a coronary artery. We also included any hospitalization due to
acute coronary syndrome in this endpoint.
e. Heart Failure (ICD-10: I50): This refers to chronic or congestive heart failure, left
ventricular failure, unspecified heart failure and heart failure requiring hospitalization.
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f. Ischemic stroke (ICD-10: I63): This includes both fatal and non-fatal cerebral
infarction due to occlusion of cerebral arteries as a result of embolism or thrombosis.
g. Cardiac arrest (ICD-10: I46.9): This comprises hospitalization or death due to cardiac
arrest.
h. All-cause mortality: This includes death from any cause.
i. Cardiovascular mortality (ICD-10: I00-I99): Any death due to disease of the
circulatory system, including coronary heart disease, stroke, hypertensive diseases,
inflammatory heart diseases, rheumatic heart diseases, and other cardiovascular
diseases.
2.4 Reporting of adjusted risk estimates
Eligible studies could report the outcome of interest in terms of adjusted relative risk
estimates (risk ratios, odds ratios, hazard ratios, standardized morbidity or mortality
ratios) and accompanying 95% confidence intervals, p-values, z-scores, or standard
errors. Observational studies that reported only crude or unadjusted risk estimates were
deemed ineligible. Trials could include unadjusted estimates including dichotomous
event data.
3. Literature search
We developed a comprehensive literature search strategy with the help of a clinical
librarian. First, we identified all possible terms and their synonyms related to this study’s
PICO (population, intervention, control and outcome) and then transferred them into a
primary search strategy for the Ovid Medline database. We used combinations of medical
subject headings (MeSH terms) and free text keywords in this search strategy to identify
all relevant articles.
The primary Ovid Medline search strategy identified 1216 articles. We pilot-tested this
strategy against relevant key articles; refined and modified it by adding further terms,
which were identified from the test articles’ mapped keywords; and examined search
strategies from related systematic reviews. In Table 1 (at the end of this chapter), we
present a final list of MeSH terms and keywords used in our search strategies.
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We limited our search to adults and human studies. Once we finalized the Ovid Medline
search strategy, we translated it into other online bibliographic databases such as
EMBASE, Cochrane library, Web of Science and Google Scholar using analogous terms
pertaining to the specific database. We searched records published from the initial
available year of indexing up to November 30, 2014 with assistance from weekly autoalert emails from each of the databases. The full search strategy is presented in Appendix
B.
Additionally, we manually searched bibliographies of eligible studies and previous
narrative and systematic reviews. We also searched abstracts in recent years from major
rheumatology, dermatology and gastroenterology conferences.
4. Screening of studies
For subsequent manipulation and review of citations, we downloaded all retrieved
citations into RefWorks, an internet-based reference management tool. We removed all
duplicate citations prior to study screening. A total of 13,479 records were then screened.
The principal investigator (AS) initially screened all records by reviewing their titles,
abstracts and keywords. Records were excluded upon initial review if they were found to
be case reports, cross-sectional studies, reviews, letters, commentaries or guidelines. If
the reviewer could not initially determine whether to include or exclude a record by
screening the title, keywords and abstract, the full text of the record was reviewed to
make a final decision. We identified a total of 187 papers for full text review.
5. Study eligibility assessment
We retrieved the full text of all 187 papers. We developed a standardized eligibility
assessment form in Microsoft Excel to rate the eligibility of these records. We pre-tested
this sheet in 20 randomly selected studies, modified it based on these results, and
finalized it (Appendix C). Two investigators, AS and DH, independently assessed the
eligibility of 187 full text reports using the pre-specified inclusion and exclusion criteria
(Table 2).
All studies were categorized as either ‘Included’ (if the study met all inclusion criteria) or
‘Excluded’ or ‘Unclear’ in the standardized eligibility form. We recorded reasons for the
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excluded and unclear studies. To determine reviewers’ agreement, we calculated Cohen’s
kappa statistic (κ).79 We interpreted the value of kappa as follows: fair agreement (0.210.40), moderate agreement (0.41-0.60), substantial agreement (0.61-0.80) and almost
perfect agreement (0.81-1.00).80 Disagreements between reviewers were resolved by reevaluation of the studies, followed by discussion and consensus.
6. Data abstraction
We created a comprehensive data abstraction form in Microsoft Excel. The form included
the following variables: study number, citation details, study characteristics, sample
characteristics, disease particulars, exposure and outcome details, and analysis and results
(Appendix D). We pilot-tested this form using five randomly selected studies and refined
it based on the results.
One reviewer (AS) abstracted data from the final list of selected studies for the following:
study accrual start and end date; inclusion and exclusion criteria; demographic
information (mean age, gender distribution); disease details such as diagnostic criteria
and disease duration; methotrexate exposure details such as exposure definition, exposure
type, exposure data source and dose of methotrexate (mean or median mg/kg); details of
outcome (outcome definition, source of outcome data); and results and analysis variables,
including number of events in each group, adjusted risk estimates with 95% confidence
intervals, variables adjusted for, dose response analyses and subgroup analyses.
7. Quality assessment of included studies
We assessed the quality of included studies using the Newcastle-Ottawa-Scale (NOS) for
non-randomized studies and the Cochrane risk of bias tool for randomized trials.1,2
7.1 Newcastle-Ottawa Scale (NOS)
The NOS was proposed by Wells et al to assess the quality of observational (nonrandomized) studies in meta-analyses. The scale was tested on systematic reviews. Its
content validity and inter-rater reliability have been established.1 Deeks et al evaluated a
total of 194 different observational study quality assessment tools, and found the NOS
was relatively easy to use, faster to complete and suitable for use in systematic reviews.81
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The developers of the NOS measured its validity and inter-rater reliability using several
cohort and case-control studies and reported an intra-class correlation of 0.88 for cohort
studies and 0.62 for case-control studies.82 In the same study, inter-rater reliability was
high for both cohort (ICC=0.94) as well as case-control studies (ICC=0.82). In contrast,
Hartling et al noted a varied range of inter-rater reliability, from slight to moderate
agreement across the different domains of NOS.82 A poster presented at the 2010
Cochrane collaboration annual colloquia by Hou et al reported fair to almost perfect
reliability for the rating of NOS items and fair to good inter-rater correlation for the total
score.83
There are two separate Newcastle-Ottawa scales for case-control and cohort studies,
respectively. The scale uses a ‘star’ rating system to adjudicate quality based on three
broad domains, namely selection and comparability of study groups, and outcome in
cohort studies and exposure in case-control studies (Appendix E).
7.2 Cochrane Risk of Bias tool
The Cochrane risk of bias tool is a widely used tool to assess the internal validity of
randomized trials (Appendix F). It addresses seven specific domains, including sequence
generation, allocation concealment, blinding of participants and personnel, blinding of
outcome assessment, incomplete outcome data, selective outcome reporting and other
issues.2 Hartling et al quantified a moderate inter-rater reliability for ‘sequence
generation’ and fair agreement for all other domains.84
8. Statistical analysis
To provide descriptive statistics, we prepared a summary data sheet in Excel from the
abstracted data. This data sheet included variables such as disease under study, disease
duration, outcome of interest, risk estimates and confidence intervals; study design, mean
age, gender distribution, exposure details, study region, accrual start date, publication
year and variables adjusted in the analysis. We double checked these data against the
relevant studies to ensure errorless entry of risk estimates and other variables for the
analysis. We used Comprehensive Meta-analysis Version 2.0 (Inglewood, NJ) for the
meta-analysis, subgroup analyses and meta-regression analyses. A two-tailed P-value of
<0.05 was considered to be statistically significant.
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8.1 Primary analysis
The primary outcome was a synthesis of cardiovascular events. We considered MTX
exposure in any form or dose for the primary analysis. Dose-response analysis was
performed in a secondary analysis.
When a single study presented stratified analyses according to gender, age group, or other
risk modifier, where each study group was an autonomous, non-overlapping unit, we used
a fixed effects model to combine these stratified results into a single study-specific risk
estimate.85 If a study presented independent effect estimates for more than one disease,
we considered each disease as a separate unit of analysis (a separate study). As our
outcomes of interest were rare, we considered similarity between different risk estimates
(odds ratio, relative risk, hazard ratio and incidence rate ratio).86 When we found a trial
with multiple comparison arms, we used data only for the methotrexate user and
methotrexate non-user (or placebo) arms to calculate risk estimates.
We calculated relative risk and its confidence interval from the number of events reported
in randomized controlled trials using the online calculator at
www.medcalc.org/calc/relative_risk.php. With the exception of randomized trials, we
took the maximally adjusted risk ratio from each trial for data synthesis. We synthesized
adjusted risk estimates using DerSimonian and Laird random-effects models and
computed pooled risk ratios (RR) with 95% confidence intervals for each outcome of
interest.87 The included studies were heterogeneous, representing different autoimmune
diseases, various study designs, dissimilar geographical areas, patients with diverse risk
of outcomes, and different methotrexate doses. The random effects model integrates these
inter-study variations into the analysis, while the fixed effects model does not.
We assessed statistical heterogeneity across the studies using Higgins’ I2 statistic.88 The I2
quantity is the proportion of observed variation that is due to real heterogeneity rather
than chance between studies. The value of I2 ranges from 0 to 100%, with zero indicating
no heterogeneity and larger values indicating progressively higher heterogeneity. Higgins
et al suggested a practical rule for I2 to classify low, moderate or substantial
heterogeneity.89 According to this rule, I2 < 25% denotes low heterogeneity; I2 = 25% to
50% denotes moderate heterogeneity, and I2 > 50% denotes substantial heterogeneity.
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8.2 Publication bias
We used funnel plots to identify publication bias, supplemented by an imputation test.90
Publication bias is one potential cause of funnel plot asymmetry. In the presence of
publication bias, the funnel plot shows an absence of studies in the extreme areas of
middle portion as well as missing studies at the bottom of the plot.91
To estimate the impact of publication bias on the effect size and obtain a bias-adjusted
effect estimate, we used Duval and Tweedie’s trim and fill method.92 This method
estimates unbiased effect size by removing or adding studies to the funnel plot, making it
symmetrical.
8.3 Secondary analysis
We synthesized studies for the secondary endpoints (all-cause mortality, cardiovascular
mortality, coronary events, heart failure and stroke) using a random effects model to
obtain pooled risk ratios.
8.4 Heterogeneity
We addressed the issue of heterogeneity for the primary outcome using subgroup
analyses and meta-regression.
8.4.1

Subgroup analysis

We pre-specified the following subgroups for the primary analysis of cardiovascular
events. We assessed MTX-by-subgroup interactions across the subgroups.
1. Disease under study: Rheumatoid arthritis carries a higher risk of cardiovascular
events than any other autoimmune disease. We carried out a subgroup analysis by
type of autoimmune disease. We explored how the effect size differed between
rheumatoid arthritis, psoriasis and other diseases (dermatomyositis, polymyositis and
systemic sclerosis).
2. Study design: All other things being equal, a prospective cohort study is generally
considered higher quality evidence than a retrospective cohort or case-control study.
Using subgroup analyses, we analyzed how the observed effect size differed between
prospective cohorts, retrospective cohorts and case-control studies for cardiovascular
events.

24

3. Study region: In this analysis, we examined the association of MTX with
cardiovascular events between North American and non-North American (European
and Asian) studies.
4. Patients with cardiovascular disease: The risk of recurrent cardiovascular events is
higher in patients with prior cardiovascular disease.93,94 We performed a subgroup
analysis to compare the effect size between studies that excluded patients with prior
cardiovascular disease and those that did not.
5. Methotrexate exposure types: We compared the effect of methotrexate in treatment
initiators versus ever-users on cardiovascular events.
6. Data source: We performed a subgroup analysis by type of data source. We explored
how the effect size differed between studies that used administrative databases as a
data source versus those that used patient medical records. Databases included
administrative pharmacy records and insurance databases.
7. Adjustment for DMARDs and other anti-rheumatic medications: To examine the
independence of the associative risk of methotrexate from concomitant diseasemodifying therapies, we computed the effect size for studies that adjusted for nonmethotrexate DMARDs and other anti-rheumatic medications in their analysis.
8. Adjustment for cardiovascular risk factors: We explored how the effect size varied
between studies that adjusted for hypertension, diabetes and dyslipidemia in their
analysis versus those that adjusted for none of these cardiovascular risk factors.
9. Adjustment for cardiovascular disease: We carried out a subgroup analysis for studies
that adjusted for cardiovascular disease in their analysis versus studies that did not.
10. Adjustment for smoking: We compared the effect size for studies that adjusted for
smoking versus studies that did not.
8.4.2

Meta-regression

We also explored heterogeneity in the primary analysis with respect to several factors
using a random effects meta-regression on a log risk ratio scale, weighted by the standard
error of the log risk ratio.95 We performed this univariate random effects meta-regression
using the unrestricted maximum likelihood estimation method. We chose this method
because it provides conservative confidence interval coverage for the point estimate.96,97
Factors assessed for heterogeneity were:

25

1. Mean age of patients: Due to the differences in cardiovascular risk factor distribution,
coronary disease is two to five times as common in middle-aged men as women.98
Similarly, age is the strongest predictor of cardiovascular disease.99 Risk of
cardiovascular disease increases with advancing age.98,100 We carried out a metaregression analysis for mean age distribution across the studies. For each study, we
collected mean age for the whole cohort. If a study reported median age, we used that
as the mean age. In case-control studies, where a study reported mean age in cases
and controls separately, we calculated the weighted average of the means.
2. Sex distribution: Autoimmune rheumatic diseases are typically more common in
women than men.101,102 Conversely men tend to be at greater risk for cardiovascular
disease than women.102 We collected the proportion of women from each study and
modelled it as a continuous variable in the meta-regression.
3. Study accrual (start year): For each study, we collected data on the accrual period. We
modelled the initial year of the accrual period as a continuous variable.
4. Publication year: We modelled the year of publication to assess whether the
association of MTX with cardiovascular events changed over time.
5. Observation time (in person-years): Several studies have suggested that the
association between autoimmune disease and cardiovascular disease is sensitive to
disease duration, study follow-up epoch and cohort type.103,104 We obtained a study
observation period in terms of cumulative person-years exposure for cohort studies.
Case-control studies were excluded from this analysis.
6. Quality of studies according to Newcastle-Ottawa Scale (NOS): We assessed quality
of observational studies using the NOS. The score ranged from 1-9, with greater
scores representing higher quality.
7. Analysis adjusted for hypertension, diabetes and dyslipidemia: Obesity, cigarette
smoking, elevated blood pressure, dyslipidemia and diabetes mellitus are considered
traditional risk factors for cardiovascular disease.10 Using meta-regression, we
modelled the studies that adjusted for hypertension, diabetes and dyslipidemia versus
those that adjusted for none of these variables.
8. Analysis adjusted for smoking: We performed meta-regression among the studies that
adjusted for smoking versus those that did not.
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9. Power score of included studies: We calculated the power for the included studies
using the formula: (1-φ (Cα-Z score) + φ (-Cα-Z score)), where Cα is the critical
value of Z associated with significance level α (for α=0.05, Cα=1.96) and Z
score=effect size/SE. This can be calculated in Excel by: 1- NORMSINV (1.96-Z
score) + NORMSINV (-1.96-Z score). We used these power scores in the metaregression to assess the effects of varying power on effect size.
We did not have sufficient studies to run a meta-regression by disease duration, as only
three studies with primary outcome data reported disease duration.
8.5 Dose-response analysis
To test for a dose-response relationship, we explored the associative risk of high and low
dose MTX on cardiovascular events. We considered the cut-point for high and low dose
MTX as defined by each study. We performed separate syntheses for high and low dose
MTX.
9. Overall quality of the evidence
We used the GRADE approach to rate the overall quality and strength of the estimated
association with cardiovascular events.105 Two investigators (AS and DH) independently
assessed the quality of the evidence. We presented the results of this assessment in a
GRADE ‘summary of findings’ table. We then reported the overall GRADE score.
10. Presentation of results
We reported this systematic review according to the PRISMA guidelines. A flow chart
was presented for the study identification and selection process. We summarized the
study characteristics, disease under study, outcome characteristics, exposure details, and
summary statistics in tabular format. We presented forest plots for the overall association
of MTX with primary as well as secondary outcomes. We used funnel plots with trimand-fill analyses to assess for publication bias.
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11. Tables
Table 1. Search terms used in the Ovid Medline search strategy
Topic
Autoimmune
diseases

Methotrexate

Mortality
outcomes

Cardiovascular
outcomes

MeSH terms
Autoimmune Diseases,
Rheumatic diseases,
Arthritis, Rheumatoid
Psoriasis
Myositis
Polymyositis
Dermatomyositis
Lupus Erythematosus, Systemic
Multiple Sclerosis
Sjogren's Syndrome
Pemphigoid, Bullous
Inflammatory Bowel Diseases
Myelitis, Transverse
Scleroderma, Systemic
Myasthenia Gravis
Anti-Neutrophil Cytoplasmic
Antibody-Associated Vasculitis
Polyarteritis nodosa
Takayasu arteritis
Methotrexate

mortality, cause of death, fatal
outcome, hospital mortality,
death, sudden cardiac death,
sudden death, death certificate,
life expectancy, life tables, vital
statistics
cardiovascular diseases
cerebrovascular diseases

Key words
Autoimmune, rheumatic,
rheumatoid, psoriatic, arthritis,
psoriasis, polymyositis,
dermatomyositis, inflammatory
myopathies, systemic lupus
erythematosus, SLE, multiple
sclerosis, Sjogren’s, bullous
pemphigoid, inflammatory
bowel disease, ulcerative colitis,
Crohn’s, IBD, systemic
sclerosis, myasthenia gravis,
Wegener’s granulomatosis,
microscopic polyangiitis,
polyarteritis, allergic and
eosinophilic granulomatosis,
Churg-strauss syndrome,
ANCA, anti-neutrophil
cytoplasmic antibody associated
vasculitis
methotrexate, amethopterin,
MTX and all possible trade
names of methotrexare
identified from online search
and EMBASE database
Mortality, death, died, die, fatal,
life expectancy, life table, Cox
model, Kaplan Meier

cardiovascular, cerebrovascular,
cardiac, myocardial, heart,
coronary, morbidity, stroke,
IHD, CHF, CVA, CVD, MI,
CHD, CAD, infarct, arrest,
disease, ischemic, failure, event,
bypass, revascularization,
disorders

Abbreviations-IHD: Ischaemic heart disease, CAD: Coronary artery disease, CHD: Coronary heart
disease, CHF: Congestive heart failure, CVA: Cerebrovascular accident, CVD: Cardiovascular disease, MI:
Myocardial infarction.
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Table 2. Study inclusion and exclusion criteria
Inclusion criteria
Cohort studies, case-control studies,
randomized controlled trials

Exclusion criteria
Cross-sectional studies, letters,
Study design
commentaries, editorials, case
reports, reviews, cross-over
trials, in vitro studies
Disease under Any of the autoimmune diseases listed Studies without one of the
in the text
listed autoimmune diseases
study
- Studies reporting cardiovascular
Studies without any of these
Outcomes of
events, cardiovascular mortality and/or endpoints
interest
all-cause mortality
- Trials reporting mortality or CV
events in MTX users and a placebo
group
Any
Country of
origin
Any
Study
duration
English articles
Non-English articles
Language
- Studies comparing outcome of
- Studies assessing exposure
Comparison
interest in MTX users versus nonother than MTX such as antiusers or placebo group, using
TNF agents, other
multivariate regression to adjust for
conventional DMARDs,
potential confounders
glucocorticoids, cytotoxic and
- Study using topical agents or
non-cytotoxic agents
phototherapy as a control group
- Studies comparing outcome
of interest in MTX users
versus an active control group
Risk
measures

Other
consideration

- Observational studies reporting any
- Observational studies
of the following adjusted risk
reporting unadjusted numbers
measures along with its 95%
or percentages of events
confidence interval or standard error
without adjusted relative risk
or p-value: incidence rate ratio, odds
measures
ratio, relative risk, hazard ratio.
- Trials without binary event
- Trials reporting binary event data
data
In case of multiple publications from the same patient population, we
selected the study with the largest sample size
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Chapter 3: Results
1. Citation screening
We initially identified a total of 14,042 potential records from bibliographic databases
and grey literature (Figure 3). We removed 563 duplicate records. We then screened
13,479 records by title, abstract and keywords to identify relevant studies. We excluded
13,292 irrelevant records. What remained were 187 potentially relevant records, for
which we retrieved full text to better assess their eligibility.
We excluded 157 studies for the reasons described in Figure 3. A total of 30 studies met
all selection criteria and were included in the meta-analysis. The kappa statistic for interrater agreement was 0.77, indicating substantial agreement.
2. INCLUDED STUDIES
2.1 Study characteristics
Appendix G presents characteristics of the included studies. There were 20 cohort
studies, 7 case-control studies and 3 randomized controlled trials. The majority of the
studies were from North America (n=17); a number were from Europe (n=10) and
relatively few from Asia (n=3). The earliest published study was by van Den Hoogen et
al in 1996 and the latest one was by Norton et al in 2014.106,107 Our review included a
total of 122,113 patients; 98,295 from cohort studies, 23,400 from case-control studies
and 418 from randomized trials.
2.2 Characteristics of disease
As per Appendix H, the majority of studies examined the effect of MTX in patients with
RA (n=21). Other autoimmune diseases studied were psoriasis (n=3), systemic sclerosis
(n=3), inflammatory polyarthritis (n=1), and myositis (n=1). Prodanowich et al studied
patients with RA as well as psoriasis.108 Two studies, Chin et al and Wu et al, included
patients with psoriatic arthritis along with psoriasis.67,109 Among the studies using RA
patients, 11 studies used American College of Rheumatology criteria for RA diagnosis,
three studies used ICD-9 diagnosis codes and four studies used rheumatologist diagnosis
as a diagnostic criterion. Three studies did not specify diagnostic criteria for the disease
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under study.68,107,110 Only 15 studies specified disease duration, which ranged from a
maximum of 12 months in Ajeganova et al to a mean of 14.5 years in Davis et al.63,75
2.3 Exposure characteristics
Appendix I describes the exposure characteristics for MTX. The included studies used
differing definitions for MTX exposure. Use of MTX for more than six months during
the observation period was considered MTX exposure in four studies.63,66,111,112 Choi et al
used the intention-to-treat concept for defining MTX therapy.113 MTX-user comparisons
included ever-users versus never-users (n=13), current-users versus non-users (n=8) and
initiators versus non-initiators (n=8). All randomized trials compared MTX users with a
placebo group.106,114,115 In these trials, we categorized MTX exposure as initiators versus
non-initiators. Exposure status was not clear in Mantel et al.110 The majority of studies
extracted MTX exposure data from patient medical records (n=16); whereas others used
administrative databases (n=11) or self-administered questionnaires (n=3) to capture
MTX exposure.
2.4 Outcome characteristics
Outcome characteristics are described in Appendix J. Most of the studies reported
composite cardiovascular events (n=7).63,70,75,108,116-118 Others reported myocardial
infarction (n=5), acute coronary syndrome (n=1), coronary artery disease (n=2), stroke
(n=4), and heart failure (n=2). Eleven studies reported all-cause mortality and only 3
studies reported cardiovascular mortality. Choi et al and Goodson et al assessed both allcause and cardiovascular mortality.111,113 Ajeganova et al and Davis et al evaluated both
cardiovascular events and all-cause mortality.63,75 All randomized controlled trials
reported mortality as an adverse event.
The following are study-specific definitions for cardiovascular events in each of seven
studies reporting the primary outcome.
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Study name

Cardiovascular events
Fatal or non-fatal myocardial infarction (MI), angina
pectoris, coronary artery bypass grafting (CABG) or

Ajeganova et al., 2013

63

percutaneous coronary intervention (PCI), peripheral
artery disease (PAD), vascular surgery, ischemic stroke,
transient ischemic attack (TIA)

Davis et al., 201375

Fatal or non-fatal MI, stroke, PCI, CABG
Ischemic heart disease (IHD), acute coronary syndrome

Gonzalez-Gay et al., 2007

116

(ACS), MI, heart failure, cerebrovascular accident
(CVA), peripheral arteriopathy
Fatal or non-fatal MI, Percutaneous transluminal coronary

Meek et al., 201470

angioplasty (PTCA), CABG, angina pectoris, acute heart
failure, CVA, death due to cardiac causes and sudden
death

Prodanowich et al., 2005108

Cardiovascular disease, cerebrovascular disease,
atherosclerosis

Tisseverasinghe et al.,
2009118

Stroke, IHD, PAD, MI

van Halm et al., 2006117

MI, CABG, PTCA, ischemic abnormality on ECG, CVA,
TIA, carotid endarterectomy and PAD

2.5 Number of events
There were a total of 4380 cardiovascular events (primary endpoints), 958 strokes, 612
diagnoses of heart failure, 2081 myocardial infarctions, 29 episodes of ischemic heart
disease, 1829 deaths and 186 cardiovascular deaths. Three studies presented only relative
risk measures without reporting the number of events.65,107,110 Prodanowich et al reported
the highest number of cardiovascular events; Wasko et al reported the highest number of
all-cause deaths; and Goodson et al reported the highest number of cardiovascular
deaths.108,111,119
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2.6 Characteristics of studies reporting primary outcome (n=7)
Seven studies included cardiovascular events as the outcome. Prodanowich et al studied
the effect of MTX in RA and psoriasis patients separately; therefore these were
considered as two separate studies. Thus, there were a total of eight studies in the metaanalysis for the primary outcome, with an aggregate sample size of 17,796 patients.
2.7 Results of individual studies
Results from individual studies are presented in Table 3 at the end of this chapter. Most
of the studies (n=16) used hazard ratios (95% confidence intervals) to report the effect of
MTX on the outcomes; two studies used rate ratios, two studies used relative risks, one
study reported incidence rate ratio and six studies used odds ratios. From the number of
events reported in three randomized trials, we calculated the relative risk and 95%
confidence interval.
A study by Meek et al70 presented a hazard ratio of 3.436 (95% CI: 1.553, 7.576) for the
protective effect of MTX against incident first cardiovascular event in RA patients. To
interpret this hazard ratio as a risk of the first cardiovascular event in MTX users versus
non-users, we took the reciprocal of it. We calculated the standard error from 95%
confidence interval, inverted it and re-calculated the 95% confidence interval to be used
in the meta-analysis.
Chin et al reported two outcomes: cerebrovascular and cardiovascular events.67 To avoid
doubling the control group by combining these outcomes into a single measure, we only
considered cerebrovascular outcomes for the analysis on stroke.
Troelsen et al assessed ischemic heart disease (IHD) and myocardial infarction (MI) as
two separate outcomes.120 There was a chance of overrepresentation of the study if we
had combined these two outcomes in a single measure. As MI is a subset of IHD, and
IHD is a more diverse outcome, we used only IHD in this meta-analysis.
Walfe and Michaud presented risk estimates for first observed MI and all MI
separately.112 We considered all MI as the outcome of interest.
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3. PRIMARY ANALYSES
3.1 Cardiovascular events
Figure 4 gives the associations from individual studies and the overall pooled estimate for
the association of MTX with cardiovascular events, analysed using random effects metaanalysis. MTX was significantly associated with a decreased risk of cardiovascular events
with a pooled risk ratio of 0.75 (95% CI: 0.65, 0.86).
The greatest effect size was observed in a study by Meek et al with a risk ratio of 0.29
(95% CI: 0.13, 0.65) and the smallest effect in Tisseverasinghe et al (RR: 0.90, 95% CI:
0.33, 2.49). Although the individual study effects were numerically protective, three
studies presented statistically non-significant effects.116-118 I2 for the overall pooled
estimate was 11%, indicating minimal heterogeneity.
4. SECONDARY ANALYSES
4.1 All-cause mortality
MTX was associated with significantly decreased all-cause mortality with a pooled risk
ratio of 0.60 (95% CI: 0.48, 0.76). In Figure 8, we have presented separate analyses for
cohort studies and randomized trials. The overall effect was statistically significant in
cohort studies (RR: 0.60, 95% CI: 0.47, 0.76), while non-significant in randomized trials
(RR: 0.69, 95% CI: 0.24, 2.00). There was moderate heterogeneity for the overall pooled
effect estimate with an I2 of 45%.
4.2 Cardiovascular mortality
Only three studies examined the association of MTX with cardiovascular
mortality.111,113,116 As shown in Figure 9, MTX was associated with reduced
cardiovascular mortality. The overall pooled risk ratio was 0.45 (95% CI: 0.26, 0.80). I2
for the pooled estimate was 33%, indicating moderate heterogeneity.
4.3 Specific cardiovascular events (as a secondary analysis)
MTX was associated with a lower risk of coronary events with a pooled risk ratio of 0.78
(95% CI: 0.67, 0.91), and a non-significantly lower risk of heart failure (RR: 0.61, 95%
CI: 0.32, 1.19) and stroke (RR: 0.67, 95% CI: 0.42, 1.09) (Figure 11).
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5. Subgroup analysis for cardiovascular events
Table 4 reports the results from subgroup analyses. Tests of interaction across the
specified subgroups were all non-significant at the p<0.05 level of significance.
6. Meta-regression for cardiovascular events
We carried out univariate random effects meta-regression for the pre-specified variables.
The results are shown in Table 5. All predictors were non-significant in the analysis.
7. Dose-response analysis
A total of three studies reported an MTX-dose analysis for cardiovascular events.69,108,117
In Figure 6, we compared the effect of high- and low- cumulative dose MTX. Low
cumulative dose MTX showed a more sizeable reduction in cardiovascular events (RR:
0.61, 95% CI: 0.51, 0.74) compared to the association for high cumulative dose MTX
(RR: 0.88, 95% CI: 0.78, 0.99). The test of significance across dose was statistically
significant (p-value: 0.001).
8. Publication bias
We assessed publication bias using funnel plots, and its impact using Duval and
Tweedie’s trim and fill method (Figures 7 for cardiovascular events and Figure 10 for allcause mortality).
For cardiovascular events, the method imputed two studies to the right of the null line to
make the plot symmetrical. The publication bias adjusted risk ratio was almost the same
as the observed risk ratio: RR 0.75 (95% CI: 0.65, 0.86) versus RR 0.76 (95% CI: 0.63,
0.92). Similarly, for all-cause mortality, the observed risk ratio remained unchanged after
adjustment for publication bias.
9. Methodological quality of included studies
We assessed the methodological quality of observational studies using the NewcastleOttawa-Scale. Appendix L and M displays the score of NOS for cohort and case-control
studies respectively. The cohort studies’ NOS score ranged from 6 to 9. Median (IQR) of
the NOS score for cohort studies was 8 (1). All seven case-control studies had an NOS
score from 6 to 8. Median (IQR) of the NOS score for case-control studies was 7 (0.5).
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Among the studies reporting the primary outcome, median (IQR) of the NOS score was 8
(1.5).
We used the Cochrane risk of bias tool to assess the methodological quality of
randomized controlled trials. In Appendix N, we have presented the review author’s (AS)
judgement for each quality item.
10. Overall quality of evidence
We used the GRADE ‘summary of findings’ table to present the overall quality of
evidence for each outcome.105 Table 7 represents the rating of the evidence. In the
GRADE system, randomized controlled trials are graded as high-quality and
observational studies as low-quality evidence. However, if there is evidence of a large
effect size, dose response gradient or implausible confounding, the quality of
observational studies should be rated up.105
All 8 studies reporting the primary outcome were observational studies. We rated this
evidence as moderate evidence due to the reported dose response gradient for low and
high dose MTX. For all-cause mortality and coronary endpoints, the evidence was
labelled as very low-quality as there was moderate heterogeneity with I2 of 45% and 30%
respectively. The evidence for cardiovascular mortality was rated very low-quality
evidence due to inconsistency (I2: 33%) and suspected publication bias. For stroke, the
evidence has both imprecision and inconsistency, and thus was labelled as very low grade
evidence. Results from heart failure studies were assessed as inconsistent and imprecise,
resulting in very low grade evidence.
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11. Tables and Figures
Figure 3. Screening and selection process for studies
Additional records identified
through other sources
(n=233)
Database updates = 194
Snowballing = 39

Records identified through
database searching
(n=13809)

Total records identified
(n=14042)

Duplicate records removed
(n=563)
Total records screened for titles,
abstracts and keywords
(n=13479)

Records excluded as irrelevant
(n=13292)

Full text studies assessed for
eligibility in duplicate
(n=187)

Studies included in quantitative
synthesis
(n=30)

Studies included in
quantitative synthesis
(n=30)

Full text studies excluded (n=157)
 Non-English language (8)
 Duplicate data or insufficient data
(9)
 Case-reports, letters, commentaries,
or editorials (37)
 Cross-sectional design or crossover RCT (3)
 Active comparators (7)
 Unrelated disease population (3)
 Studies without relevant outcomes
(8)
 Studies with no outcome data for
MTX (55)
 No assessment of an independent
effect of MTX on outcomes (18)
 No statistical measures presented
(1)
 Studies with unadjusted data (8)
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Table 3. Results of individual studies
Study

Observation time

Ajeganova
et al., 2013

9405
person-years

Cardiovascular events
All-cause mortality

Bernatsky
et al., 2005

51301
person-years

CHF requiring
hospitalization

BozaiteGluosniene
et al.,2011

Not specified

CAD

Chiang et
al., 2013

Chin et al.,
2013

Choi et al.,
2002
Cohen et
al., 2001
Davis et al.,
2013
Edwards et
al., 2008

Median
4.7 years
Cerebrovascular
event: psoriasis:
3428.5 ± 11.2 and
PsA: 3235.2 ± 60.4
days, CV events:
psoriasis:3275.0 ±
14.5 and PsA:
3085.1 ± 70.5 days
91007
person-months
24 months

Outcome

Number of
events
177
151

Effect
measure

520

Rate ratio

0.80 (0.60 - 1.00)

Not specified

HR

0.54 (0.37 - 0.77)

Ischemic stroke

86

HR

1.47 (0.64 - 3.42)

Cerebrovascular events
Cardiovascular events

406
688

HR

0.45 (0.23 - 0.85)
0.48 (0.29 - 0.81)

Age, sex, HTN, diabetes,
dyslipidemia and phototherapy

All-cause mortality
Cardiovascular mortality

191
84

HR

0.40 (0.20 - 0.80)
0.30 (0.20 - 0.70)

Age, sex, RF, calendar year, disease
duration, smoking, education, HAQ score,
PtGA, joint counts, ESR, prednisone use,
no. of other DMARDs

3

RR

1.34 (0.12 - 14.7)

All-cause mortality

HR

Risk estimates
(95% CI)
0.72 (0.53 - 0.99)
0.99 (0.71 - 1.38)

3743
person-years

Cardiovascular events
All-cause mortality

97
252

HR

0.66 (0.44 - 1.00)
0.75 (0.58 - 0.97)

Not specified

MI

966

IRR

0.86 (0.74 – 1.00)

Variables adjusted for
Age, sex, smoking status at inclusion,
HTN, DM, hyperlipidemia
Age, sex, cohort, comorbidities, current
DMARDs, use of NSAIDs, COX-2
inhibitors, glucocorticoids
Age, sex, HTN, hyperlipidemia, DM,
RF, BMI, blood pressure, LDL, ESR,
Hydroxychloroquine, MTX, corticosteroid
and NSAID use
Age, sex (male), HTN, DM, dyslipidemia,
chronic kidney disease, CAD and AF

Multiple patient demographic
and RA severity
Age, sex, BMI, HTN, DM, smoking
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Study

Observation time

Outcome

Number of
events

Effect
measure

Risk estimates
(95% CI)

GonzalezGay et al.,
2007

Mean (IQR):
13.4, (10-16) years

Cardiovascular events
Cardiovascular mortality

39
17

HR

0.86 (0.39 - 1.80)
0.86 (0.28 - 2.69)

Age at disease onset and sex

Goodson et
al., 2008

10 years

All-cause mortality
Cardiovascular mortality

203
85

OR

0.59 (0.35 - 0.97)
0.53 (0.25 - 1.14)

Age, sex, joint counts, RF, nodules, RA,
NSAIDs, steroids, CRP, smoking, HAQ,
number of comorbid medications used

Lan et al.,
2012

Not specified

Cerebrovascular event

399

HR

0.50 (0.27 - 0.92)

HTN, DM, dyslipidemia, age and sex

MI

53

HR

0.85 (0.40 - 1.84)

Age, sex, history of MI, DM, HTN,
hyperlipidemia and use of corticosteroid

Not specified

OR

1.10 (0.60 – 2.20)

Levesque et
al., 2013
Mantel et
al., 2014

2,386.4
person-years
(MTX exposure)
Average
5.3 years

Acute coronary syndrome

Meek et al.,
2014

1380
person-years

Cardiovascular event

29

HR

0.29 (0.13, 0.65)

Mikuls et
al., 2011
Myasoedov
a et al.,
2011

2314
person-years

All-cause mortality

138

HR

0.63 (0.42 - 0.96)

7692
person-years

Heart failure

92

HR

0.40 (0.20 – 0.80)

Nadareishvi
li et al.,
2008

Mean (IQR):
3.9 (2.0 – 6.0)
Years

Ischemic stroke

67 cases

OR

0.77 (0.39-1.54)

Norton et
al., 2014

Not specified

All-cause mortality

Not specified

HR

0.40 (0.25 - 0.64)

Median
1.5 years

All-cause mortality

10

RR

0.44 (0.12-1.56)

Pope et al.,
2001

Variables adjusted for

Age, sex, year of RA diagnosis and study
center*
CV risk factors, inflammatory parameters,
disease duration, presence of IgM RF
and/or anti-CCP antibodies, use of antiinflammatory immunosuppressive therapy
Age, race, BMI, comorbidities
Age, sex, calendar year, CV risk factors,
CHD, RF positivity, RA duration, ESR
and severe ExRA
(Age, sex, calendar time)*
HAQ, total joint replacement, RA
duration, low dose aspirin, comorbidity
index (0-9 for 11 comorbidities)
Demographic and clinical features at
baseline, confounding by indication of
treatment effect
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Study

Observation time

Outcome
Cardiovascular events
(psoriasis)
Cardiovascular events
(RA)

Number of
events

Effect
measure

Prodanowic
h et al.,
2005

Not specified

Suissa et
al., 2006

166194
person-years

MI

558

Rate ratio

0.81 (0.60 - 1.08)

Tisseverasi
nghe et al.,
2009

Mean (SD):
4 (3.7) years

Cardiovascular events

80

RR

0.90 (0.30 – 2.30)

Troelsen et
al., 2007
van den
Hoogen et
al., 1996
van Halm et
al., 2006

1799
person-years

IHD
MI

29
12

HR

0.60 (0.20 – 1.80)
0.70 (0.10 – 5.00)

All-cause mortality

3

RR

1.41 (0.14 -13.85)

5649
person-years

Cardiovascular events

Cases: 72

OR

0.47 (0.07-3.23)

Wasko et
al., 2013

40,722
patient-years

All-cause mortality

666

HR

0.30 (0.09 – 1.03)

Wolfe and
Michaud,
2008

Mean (IQR):
3 (0.5 – 8.5)
Years

MI (All)
MI (First MI)

283
223

OR

0.90 (0.70 - 1.20)
0.90 (0.70 - 1.20)

All-cause mortality

212

OR

0.51 (0.37-0.72)

Wolfe et al.,
2003

48 weeks

88063
person-months

1869

Risk estimates
(95% CI)
0.73 (0.55-0.98)

RR
2017

0.83 (0.71-0.96)

Variables adjusted for

Age, sex, DM, HTN, dyslipidemia, other
medications (FA, B6, B12)
Age, DMARDs, other anti-RA drugs,
IHD, PAD, other CVD, DM, respiratory
illness
Comorbidities, steroid, NSAID, Cox-2
inhibitors, immunomodulators, data source
for MI diagnosis, h/o coagulopathy and/or
exposure to aspirin, warfarin or Low
molecular weight heparin
Age and sex

Age, sex, smoking, RA duration, HTN,
DM, hypercholesterolemia
Age, education level, sex, BMI, HAQ
score, ethnicity, RA duration, HTN, CAD,
DM, stroke, prednisone, TNF inhibitors,
non-MTX DMARDs, NSAIDs, and cox-2
inhibitors and other comorbidities
Education, ethnicity, smoking, DM,
aerobic exercise, HTN, comorbidity index
from 11 present and past conditions, lowdose aspirin, BMI, baseline MI status,
PAS score, joint replacement status, RA
duration
Age, sex, HAQ score, MTX (timevarying), RA and disease factors
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Study
Wu et al.,
2012

Observation time
42424
person-years

Outcome

MI

Number of
events

Effect
measure

Risk estimates
(95% CI)

221

HR

0.52 (0.31-0.85)

Variables adjusted for
Age, sex, person-years among the cohorts,
CV risk factors, medications that are
known to reduce MI risk

Abbreviations: HTN: hypertension, DM: diabetes mellitus, BMI: Body Mass Index, RF: rheumatoid factor, LDL: low density lipoprotein, ESR: erythrocyte
sedimentation rate, NSAID: non-steroidal anti-inflammatory drug, CAD: coronary artery disease, AF: atrial fibrillation, HAQ: Health Assessment Questionnaire, PtGA:
patient global assessment of disease activity, IRR: incident rate ratio, CRP: C-reactive protein, ExRA: extra-articular manifestations of RA, RCT: randomized controlled
trials
* Variables matched in study design
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Figure 4. Effect of MTX on primary outcome (cardiovascular events)
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Table 4. Subgroup analysis for the primary outcome (cardiovascular events)

Subgroup

# of
studies

Risk ratio
(95% CI)

I2

Q statistics
(P-value)
(Test of
interaction)

Disease
RA
6
0.72 (0.58, 0.89)
34.71
Psoriasis
1
0.73 (0.48, 1.10)
0.00
0.17 (0.92)
Others (PM, DM)
1
0.90 (0.31, 2.60)
0.00
Study design
Prospective cohort
4
0.66 (0.51, 0.84)
37.09
Retrospective cohort
2
0.80 (0.67, 0.96)
0.00
1.60 (0.45)
Case-control
2
0.78 (0.31, 1.90)
0.00
Study region
America
4
0.79 (0.68, 0.91)
0.00
1.27 (0.26)
Europe
4
0.66 (0.50, 0.87)
38.66
Study excluded patients with history of CVD
Yes
6
0.75 (0.63, 0.88)
30.91
0.10 (0.75)
No
2
0.69 (0.46, 1.05)
0.00
MTX exposure type
Initiators
2
0.56 (0.39, 0.80)
68.59
3.27 (0.07)
Ever-users
6
0.79 (0.70, 0.90)
0.00
Data source for MTX exposure
Database
3
0.71 (0.54, 0.93)
0.00
0.13 (0.72)
Medical records
5
0.75 (0.62, 0.91)
42.69
Adjusted for DMARDs/other anti-rheumatic medications in the analysis
Yes
2
0.45 (0.24, 0.84)
65.80
2.88 (0.09)
No
6
0.78 (0.70, 0.88)
0.00
Adjusted for hypertension, diabetes and dyslipidemia in the analysis
Yes
6
0.74 (0.63, 0.88)
31.02
0.06 (0.80)
No
2
0.71 (0.47, 1.05)
0.00
Adjusted for CVD in the analysis (omitted studies which excluded patients with CVD)
Yes
1
0.90 (0.32, 2.54)
0.00
0.14 (0.71)
No
7
0.74 (0.63, 0.86)
22.93
Adjusted for smoking in the analysis
Yes
3
0.63 (0.48, 0.85)
54.13
1.98 (0.16)
No
5
0.80 (0.70, 0.90)
0.00
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Table 5. Meta-regression results for primary outcome (cardiovascular events)
Covariate
Mean age (years)
% Female
Accrual start (year)
Publication year
Observation time (person-years)
Quality of studies according to NOS
Analysis adjusted for HTN, DM and
dyslipidemia
Analysis adjusted for smoking
Analysis adjusted for hypertension
Analysis adjusted for diabetes
Power score of included studies

Estimated β
coefficient
(95% CI)
-0.008 (-0.065, 0.048)
-0.002 (-0.007, 0.002)
-0.030 (-0.071, 0.010)
-0.028 (-0.061, 0.005)
0.000 (-0.000, 0.000)
0.072 (-0.062, 0.208)

p- Value

τ2

0.77
0.28
0.15
0.10
0.31
0.29

0.000
0.000
0.000
0.000
0.000
0.000

0.101 (-0.279, 0.483)

0.60

0.000

-0.225 (-0.539, 0.088)
0.101 (-0.279, 0.483)
0.101 (-0.279, 0.483)
0.708 (-0.002, 1.419)

0.16
0.60
0.60
0.05

0.000
0.000
0.000
0.000

Figure 5. Association of MTX with the primary outcome by study design
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Figure 6. MTX dose response analysis for the primary outcome (cardiovascular
events)

(Low cumulative MTX dose: cumulative dose <1.56 g (in Lan et al), or less than
median dose (in Prodanowich et al); High cumulative MTX dose: cumulative dose
>1.56 g (in Lan et al), or more than median dose (in Prodanowich et al and van Halm et
al))

Figure 7. Funnel plot: Effect of MTX on primary outcome (cardiovascular events)
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Figure 8. Effect of MTX on all-cause mortality (secondary outcome)

Figure 9. Effect of MTX on cardiovascular mortality (secondary outcome)
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Figure 10. Funnel plot: Effect of MTX on all-cause mortality (secondary outcome)

47

Figure 11. Effect of MTX on cardiovascular diseases (secondary outcome)
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Table 6. Summary table of effect of MTX on different outcomes
# of studies

Random effects
RR (95% CI)

I-squared

8

0.75 (0.65, 0.86)

11%

All-cause mortality
Cardiovascular
mortality
Coronary endpoints

11

0.60 (0.48, 0.76)

41%

3

0.45 (0.26, 0.80)

33%

8

0.78 (0.67, 0.91)

30%

Stroke

4

0.67 (0.42, 1.09)

48%

Heart failure

2

0.61 (0.32, 1.19)

70%

Outcome
Primary outcome
Cardiovascular events
Secondary outcomes
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Table 7. Summary of findings
Question:

Is methotrexate associated with a lower risk of cardiovascular events in patients with autoimmune disease?

Population:

Patients with autoimmune disease (RA, psoriasis, psoriatic arthritis, systemic sclerosis, myositis, inflammatory polyarthritis)

Intervention: MTX
Comparison: MTX non-user group
Outcome:
Outcome

Cardiovascular events, all-cause mortality, cardiovascular mortality, coronary endpoints, and stroke
Risk of
bias

Cardiovascular
likely1
events
All-cause
mortality

7

likely

Cardiovascular
likely9
mortality
Coronary
endpoints

Stroke

14

likely

17

likely

Publication
bias

Number of
participants
(studies)

Relative
effect
(95% CI)

Quality of
evidence
(GRADE)

17796
(8)

0.75
(0.65, 0.86)

15160
(11)

0.60
(0.48, 0.76)

very low3,4,5,7,8

Inconsistency

Indirectness

Imprecision

no serious
inconsistency2

no serious
indirectness3

no serious
imprecision4

no serious
indirectness3

no serious
imprecision4

no serious
indirectness3

no serious
strongly
imprecision11 suspected12

2345
(3)

0.45
(0.26, 0.80)

very low3,9,10,11,12

no serious
indirectness3

no serious
imprecision4

66248
(8)

0.78
(0.67, 0.91)

very low3,4,5,13,14

18182
(4)

0.67
(0.42, 1.09)

very low3,5,15,16,17

8

inconsistency

10

inconsistency

13

inconsistency

15

inconsistency

no serious
indirectness3

imprecision16

5

not likely

5

not likely

5

not likely

5

not likely

moderate1,2,3,4,5,6
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Heart failure

1

likely18

inconsistency19

no serious
indirectness3

imprecision16

Undetected20

6515
(2)

0.61
(0.32, 1.19)

very
low3,16,18,19,20

median score of Newcastle-Ottawa scale was 8 (interquartile range (IQR): 1.5), however, all included studies were observational
overlaping CIs, non-significant p for heterogeneity and I2: 11%, suggesting minimal heterogeneity
3
patients (autoimmune disease), intervention (MTX) and outcome were consistent
4
CI of the overall effect does not include null value. Also, a number of events and total patients were large enough to achieve adequate power
5
publication bias adjusted estimate didn’t change considerable from the observed estimate
6
dose-response gradient was observed in the subgroup analysis, showing higher effect with low dose MTX
7
median score of New-castle-Ottawa scale was 9 (IQR: 1.25) for cohort studies; and the overall assessment for RCTs suggests a low risk of bias, however, the
majority of included studies were observational
8
significant p value for heterogeneity and I2: 45%, suggesting moderate heterogeneity
9
median score of New-castle-Ottawa scale was 8 (IQR: 0.5), however, all included studies were observational
10
non-overlapping CIs, non-significant p value for heterogeneity and I2:33%, suggesting moderate heterogeneity
11
CI of the overall estimate does not include null value. A total number of events was 433 with >30% of relative risk reduction
12
publication bias adjusted estimate differed from the observed estimate
13
non-overlapping CIs with I2: 30%
14
median score of New-castle-Ottawa scale was 8 (IQR: 1.25), however, all included studies were observational
15
non-overlapping CIs, non-significant p value for heterogeneity and I2:48%, suggesting moderate heterogeneity
16
wide CI for the overall estimate which includes null value; and point estimate showed an extreme benefit
17
median score of New-castle-Ottawa scale was 8 (IQR: 0), however, all included studies were observational
18
median score of New-castle-Ottawa scale was 8 (IQR: 1), however, all included studies were observational
19
non-overlapping CIs and I2:70%, suggesting substantial heterogeneity
20
publication bias could not be tested for n = 2 studies for heart failure
2
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Chapter 4: Discussion

1. Summary of findings
Our systematic review and meta-analysis suggests that MTX is associated with a 25%
reduction in cardiovascular events in patients with autoimmune disease. GRADE
assessment labelled this as moderate evidence, meaning that the true effect is close to the
observed effect but there is a possibility that it is considerably different. In our search, we
included all autoimmune diseases for which MTX is recommended as therapy. However,
we found studies in RA, psoriasis, psoriatic arthritis and myositis only. The statistical
heterogeneity for the pooled effect estimate was 11%. We explored this heterogeneity in
subgroup analyses and meta-regression according to a variety of patient and study
characteristics. None of the subgroup analyses or meta-regression predictors were
statistically significant.
A similar direction of effect was observed for all-cause mortality. MTX was associated
with a 40% reduction in all-cause mortality in patients with RA, systemic sclerosis and
inflammatory polyarthritis. This finding was accorded very low GRADE evidence. We
included three RCTs reporting mortality as an adverse event in the synthesis of this effect
estimate. These trials were of short duration and small sample size, so the confidence
intervals for individual trials as well as the pooled effect were wide. These trials were
underpowered for reporting mortality outcomes. Therefore, this result should be treated
with caution. The pooled effect from cohort studies also indicated 40% lower risk for
mortality with a narrow confidence interval. This result from the cohort studies seems
adequately powered, with the total number of patients studied and observed events equal
to 14,742 and 1684 respectively.
There was a clear association of MTX with cardiovascular mortality with a 55% lower
risk in patients with RA and inflammatory polyarthritis. This was very low GRADE
evidence due to inconsistency (I2 = 33%) and publication bias, suggesting that the true
effect is likely considerably different from the observed effect.
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MTX was associated with a lower risk of coronary events in patients with RA, psoriasis
and psoriatic arthritis. A statistically significant 22% lower risk was observed for
coronary endpoints in patients receiving MTX. However, the evidence was labelled as
very low GRADE evidence because of the inconsistency in effect across studies (I2 =
33%).
There was no clear effect of MTX on stroke despite the overall large sample size of
18,182. Similarly there was not clear association for heart failure. For stroke, this may be
due to the diverse etiology of cerebrovascular disease, with atherosclerosis accounting for
only 20% of cases. Heart failure is also diverse and may be due to different causes (e.g.
viral, idiopathic, valvular), some of which may not be amenable to MTX exposure.
Due to the low prevalence of ANCA-associated vasculitis, studies assessing MTX and
cardiovascular disease are lacking. Additionally, cardiac involvement may be different in
vasculitis than in common rheumatic conditions.121
2. Exploratory findings
The included studies reported varied types of MTX exposure. It is difficult to identify
exposure status with certainty in real-world practice, particularly given such issues as
non-compliance and temporary treatment discontinuation due to remission or side effects.
Several included studies compared the cardioprotective effect of MTX in initiators versus
non-initiators and ever-users versus never-users. To assess the association as per
“intention-to-treat” analysis, we limited our subgroup analysis to initiators versus noninitiators and reported a 44% lower risk of cardiovascular events. However, this pooled
analysis is not free from heterogeneity (I2 = 68%). We also assessed the effect of MTX in
studies adjusted for other non-MTX disease-modifying anti-rheumatic drugs and found a
55% lower risk of cardiovascular events in association with MTX exposure. But again,
substantial heterogeneity (I2 = 66%) should be considered before interpreting this result.
We found a consistent effect of MTX across different strata. The effect was constant in
patients from American and European countries where different health care systems exist.
The effect was also consistent across mean age, suggesting its applicability to different
patients regardless of age. However, the results from this meta-regression produce an

53

ecological fallacy. A decrease in the risk of cardiovascular events with one unit increase
in mean age is an association observed between two group-level variables, which may not
resembles the individual level association. These results would not be as robust as that of
regression analysis using individual patient data. Finally, the results were consistent
across publication and accrual years.
3. Dose-response
Both low and high cumulative dose MTX treatments are associated with significant
reductions in cardiovascular events. However, low cumulative dose MTX treatment
showed more than three times the cardioprotective effect of high cumulative dose MTX
treatment (39% versus 12% reduction). The difference in effect between the two groups
was statistically significant (p = 0.001).
The difference in the cardioprotective effect of low and high dose MTX might be
explained by differences in their mechanism of action, safety profile, tolerability and
treatment durability. High-dose MTX is commonly used in cancer treatment, while lowdose is recommended for the treatment of systemic inflammatory rheumatic diseases.77,122
High-dose MTX acts on rapidly growing cells through anti-proliferative and cytotoxic
mechanisms. It inhibits dihydrofolate reductase enzyme and stops de novo synthesis of
DNA, RNA, thymidylates and proteins.122,123 As discussed in Chapter 1, low-dose MTX
mainly exerts an anti-inflammatory effect.123 Increased systemic inflammation is known
to accelerate atherosclerosis; therefore, the anti-inflammatory mechanism of low-dose
MTX may play a crucial role in preventing cardiovascular disease. An alternate
explanation is that patients requiring high-dose MTX were sicker than patients requiring
low-dose MTX, and therefore there may be confounding by disease severity.
4. Strengths
In this systematic review, we searched for studies with populations having those
autoimmune diseases for which MTX is used as either first, second or third line therapy;
Micha et al included patients with only RA and psoriasis.72 In addition to RA and
psoriasis, we identified studies assessing MTX in systemic sclerosis, myositis and
inflammatory polyarthritis.
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We executed a systematic literature search of more than 13,000 citations using a
comprehensive search strategy; we identified studies from major databases such as Ovid
Medline, EMBASE, Cochrane library and Web of Science, as well as different grey
literature sources. Using detailed pre-specified inclusion and exclusion criteria, we
adjudicated studies independently and in duplicate to increase the validity of the results.
We identified observational studies for the primary outcome, representing patients treated
in real world clinical settings. In addition to cardiovascular events, we assessed the
association of MTX with cardiovascular mortality and all-cause mortality, as well as
coronary events, stroke and heart failure. To assess an independent and less confounded
effect of MTX, we only included studies that reported adjusted risk estimates. MTX can
cause severe adverse events such as hepatotoxicity, pulmonary toxicity, severe infection,
lymphoproliferative disorders and nephrotoxicity which, consequently, could lead to
death.124 To properly weigh the risks and benefits of MTX on mortality, we included
randomized controlled trials that reported mortality as an adverse event.
Despite the minimal heterogeneity of the overall pooled estimate (11%), we checked for
consistency across study design, study region, type of autoimmune disease, and presence
of adjustment for cardiovascular risk factors.
We used the established GRADE system to rate the overall quality of evidence for the
association of MTX with the reported outcomes. Previous meta-analyses have not rated
overall quality for their reported outcomes.72,73
5. Limitations
We found only observational studies for the primary outcome. These studies are not free
from confounding by selection bias and indication bias. As we discussed earlier in
chapter-1, these may either underestimate or overestimate the association. Thus, the
results should be interpreted with caution. We included only adjusted risk estimates in the
meta-analysis to reduce the impact of confounding. However, residual confounding by
unmeasured confounders could give rise to biased effect estimates.
The majority of studies did not adjust for the severity of the underlying disease, which
could cause a protective association of MTX to be underestimated. Conversely, by
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decreasing folate levels, MTX can cause hyperhomocysteinemia, a known risk factor for
cardiovascular disease.125,126 Most of the included studies did not adjust for concomitant
folic acid therapy in their analyses. As well, we identified only four studies reporting
associations of MTX for high and low doses.
Some studies used insurance claim data to assess MTX exposure.63,75,118 Therefore,
detailed information regarding treatment duration, doses and compliance were not
available. Further, none of the studies assessing the primary outcome included MTX as
time-varying covariate in their analysis. Thus, authors assumed that patients had
complied with prescribed treatment. This may present dilution bias in the results; real
effects may be considerably stronger.
We were unable to carry out meta-regression for disease duration, an important covariate
predicting cardiovascular risk in rheumatic diseases;127 only three studies reported disease
duration for the primary outcome. Different studies adjusted for different covariates in
their statistical models. However, all studies showed a similar direction of effect with
minimal statistical heterogeneity. Most of the studies failed to report the route of
administration for MTX treatment. Thus, our results cannot distinguish between oral and
subcutaneous administration.
Only one reviewer screened the articles for titles, abstracts and keywords, thus some
subjectivity and the risk of incorrectly discarding relevant reports cannot be neglected.128
A further limitation is that this review was restricted to English language studies.
Excluding non-English publications may introduce bias and reduce the precision of
estimates of treatment effects. It has been shown that trials with positive results are more
likely to be published in English.129 However, Morrison et al found no evidence of bias
from the use of language restrictions in systematic reviews.130
6. Implications for practice
MTX in autoimmune diseases (RA, psoriasis, psoriatic arthritis and myositis) is
associated with a reduced incidence of cardiovascular events. Low-dose MTX offers
more protective effect than high-dose MTX and is known to cause less toxicity.123
Treatment with MTX may improve physical activity in patients with rheumatic

56

autoimmune disease, and subsequently reduce the risk of diabetes, hypertension and
obesity. Associations with all-cause mortality and cardiovascular mortality were clear,
but evidence was graded as very low quality. MTX was not clearly protective in
associations with stroke and heart failure. Results of this meta-analysis cannot be
generalized to all MTX treated autoimmune diseases, because of lack of potential
evidence for ulcerative colitis, Crohn’s disease, systemic lupus erythematosus, transverse
myelitis, multiple sclerosis, myasthenia gravis, vasculitis and other autoimmune diseases.
7. Implications for research
As noted, MTX may be associated with several adverse effects. Assessment of the true
extent of MTX therapy on cardiovascular outcomes is needed. Currently, the
Cardiovascular Inflammation Reduction Trial (CIRT) is investigating the antiinflammatory effect of low-dose MTX in patients with prior myocardial infarction.61,62
CIRT is testing MTX in patients with high cardiovascular risk, representing a small
subpopulation of cardiovascular patients who do not have autoimmune disease.
Regardless of this caveat, results from this well-powered trial could address the efficacy
and safety of low-dose MTX as noted in our meta-analysis.
We found numerically protective but statistically non-significant effects of MTX on heart
failure and stroke. Further high quality research is needed to assess any protective effect
of MTX on heart failure and stroke.
Other autoimmune diseases such as systemic lupus erythematosus, inflammatory bowel
disease, bullous pemphigoid, ANCA associated vasculitis and Takayasu’s arteritis carry
high risks of cardiovascular events and death.31,33,41,42,43,44,50 As we noted, MTX is a
treatment option for these diseases. At present, almost no evidence exists on the
association of MTX with cardiovascular disease and mortality for these autoimmune
diseases. Further research is needed to define the association of MTX with cardiovascular
disease and mortality in these diseases. Such research, in juxtaposition with our metaanalysis, would broaden the MTX knowledge base across a wide range of diseases.
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8. Conclusion
In conclusion, early intervention with low-dose MTX together with careful monitoring in
patients with autoimmune disease such as RA, psoriasis, psoriatic arthritis or myositis is
recommended. This may not only control the underlying disease but hopefully also
reduce the risk of cardiovascular disease by 25% (if the association we have detected is
causal). MTX can cause adverse effects, and in such cases, benefits need to be weighed
against risks.
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Appendices
Appendix A. Preferred Reporting Item for Systematic Reviews and Meta-analysis (PRISMA) guidelines
Section/Topic
Title
Structured
summary
Rationale
Objectives
Protocol and
registration
Eligibility
criteria
Information
sources
Search
Study selection
Data collection
process

Item
Checklist item
No.
1
Identify the report as a systematic review, meta-analysis, or both.
Provide a structured summary including, as applicable: background; objectives; data sources;
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods;
2
results; limitations; conclusions and implications of key findings; systematic review registration
number.
3
Describe the rationale for the review in the context of what is already known.
Provide an explicit statement of questions being addressed with reference to participants,
4
interventions, comparisons, outcomes, and study design (PICOS).
Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if
5
available, provide registration information including registration number.
Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g.,
6
years considered, language, publication status) used as criteria for eligibility, giving rationale.
Describe all information sources (e.g., databases with dates of coverage, contact with study
7
authors to identify additional studies) in the search and date last searched.
Present full electronic search strategy for at least one database, including any limits used, such
8
that it could be repeated.
State the process for selecting studies (i.e., screening, eligibility, included in systematic review,
9
and, if applicable, included in the meta-analysis).
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate)
10
and any processes for obtaining and confirming data from investigators.

Page
number
ii
ii
13
13
16
16
18
18, 72
18
20
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Section/Topic
Data items
Risk of bias in
individual
studies
Summary
measures
Synthesis of
results
Risk of bias
across studies
Additional
analyses
Study selection
Study
characteristics
Risk of bias
within studies
Results of
individual
studies
Synthesis of
results

Item
No.
11
12
13
14
15
16
17
18
19
20
21

Checklist item
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any
assumptions and simplifications made.
Describe methods used for assessing risk of bias of individual studies (including specification of
whether this was done at the study or outcome level), and how this information is to be used in
any data synthesis.
State the principal summary measures (e.g., risk ratio, difference in means).
Describe the methods of handling data and combining results of studies, if done, including
measures of consistency (e.g., I2) for each meta-analysis.
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication
bias, selective reporting within studies).
Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression),
if done, indicating which were pre-specified.
Give numbers of studies screened, assessed for eligibility, and included in the review, with
reasons for exclusions at each stage, ideally with a flow diagram.
For each study, present characteristics for which data were extracted (e.g., study size, PICOS,
follow-up period) and provide the citations.
Present data on risk of bias of each study and, if available, any outcome level assessment (see
item 12).
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data
for each intervention group (b) effect estimates and confidence intervals, ideally with a forest
plot.
Present results of each meta-analysis done, including confidence intervals and measures of
consistency.

Page
number
-20
21
22
23
23
36
29
34
41
32
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Section/Topic
Risk of bias
across studies
Additional
analysis
Summary of
evidence

Item
No.
22
23
24

Limitations

25

Conclusions

26

Funding

27

Checklist item
Present results of any assessment of risk of bias across studies (see Item 15).
Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, metaregression [see Item 16]).
Summarize the main findings including the strength of evidence for each main outcome; consider
their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g.,
incomplete retrieval of identified research, reporting bias).
Provide a general interpretation of the results in the context of other evidence, and implications
for future research.
Describe sources of funding for the systematic review and other support (e.g., supply of data);
role of funders for the systematic review.

Page
number
42
42
49
54
56
--
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Appendix B. Search strategy
Ovid MEDLINE (1946 to Present)
1. Autoimmune Diseases/
2. Rheumatic Diseases/
3. Arthritis, Rheumatoid/
4. exp Psoriasis/
5. exp Polymyositis/
6. Myositis/
7. exp Lupus Erythematosus, Systemic/
8. exp Multiple Sclerosis/
9. Sjogren's Syndrome/
10. Pemphigoid, Bullous/
11. exp Inflammatory Bowel Diseases/
12. Myelitis, Transverse/
13. exp Scleroderma, Systemic/
14. Myasthenia Gravis/
15. exp Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/
16. Polyarteritis Nodosa/
17. Takayasu Arteritis/
18. (autoimmune adj (disease* or disorder*)).tw.
19. (rheumatic adj (disease* or disorder*)).tw.
20. rheumatoid arthritis.tw.
21. psoriasis.tw.
22. psoriatic arthritis.tw.
23. polymyositis.tw.
24. dermatomyositis.tw.
25. (inflammatory adj2 myopath*).tw.
26. systemic lupus erythematosus.tw.
27. (SLE and lupus).tw.
28. multiple sclerosis.tw.
29. sjogren*.tw.
30. (bullous adj2 pemphigoid).tw.
31. inflammatory bowel disease*.tw.
32. (IBD and (inflammatory and bowel)).tw.
33. Crohn*.tw.
34. ulcerative colitis.tw.
35. transverse myelitis.tw.
36. systemic sclerosis.tw.
37. systemic scleroderma.tw.
38. myasthenia gravis.tw.
39. wegener* granulomatosis.tw.
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40. microscopic polyangiitis.tw.
41. microscopic polyarteritis.tw.
42. (granulomatosis adj2 polyangiitis).tw.
43. allergic granulomatosis.tw.
44. eGPA.tw.
45. eosinophilic granulomatosis.tw.
46. churg strauss syndrome*.tw.
47. takayasu arteritis.tw.
48. (ANCA adj2 vasculitis).tw.
49. anti neutrophil cytoplasmic antibody associated vasculitis.tw.
50. or/1-49
51. Methotrexate/
52. methotrexate*.tw.
53. MTX.tw.
54. (abitrexate or amethopterine or ametopterine or antifolan or artrait or atrexel or
bendatrexat or biotrexate or carditrex or canceren or dermotrex or ebetrex or emtexate
or emthexat or emthexate or emtrexate or enthexate or farmitrexat or farmitrexate or
farmotrex or folex or ifamet or imeth or lantarel or ledertrexate or maxtrex or metex
or methoblastin or methohexate or methotrate or methotrexat or methotrexato or
methoxtrexate or methrotrexate or meticil or metoject or metothrexate or metotrexat
or metotrexate or metotrexin or metrex or mexate or mpi 5004 or mpi5004 or
neotrexate or novatrex or nsc 740 or nsc740 or otrexup or reumatrex or rheumatrex or
texate or texorate or trexall or trexan or xaken or zexate).tw.
55. amethopterin.tw.
56. or/51-55
57. Mortality/
58. Cause of Death/
59. Fatal Outcome/
60. Hospital Mortality/
61. Mortality, Premature/
62. Death/
63. Death, Sudden/
64. Death, Sudden, Cardiac/
65. Life Expectancy/
66. Life Tables/
67. Vital Statistics/
68. mortality.fs.
69. mortalit*.tw.
70. (death or dead or die or died or dies).tw.
71. ((hazard* or cox) adj2 (model* or regression*)).tw.
72. (sudden adj2 death).tw.
73. kaplan meier*.tw.
74. (life table* or lifetable*).tw.
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75. or/57-74
76. exp Cardiovascular diseases/
77. exp Cerebrovascular Disorders/
78. (cardiac adj2 (event* or arrest* or failure)).tw.
79. (cardiovascular adj2 (disease* or event* or disorder*)).tw.
80. (cerebrovascular adj2 (disease* or event* or disorder* or accident*)).tw.
81. (myocardi* adj2 (infarct* or revascular* or isch?emi*)).tw.
82. (morbid* adj2 (heart* or coronar* or ischaem* or ischem* or myocard*)).tw.
83. (heart adj (infarct* or arrest* or attack* or failure or event* or bypass*)).tw.
84. (coronary adj (disease* or event* or bypas* or graft*)).tw.
85. (Coronary adj (heart or artery) adj disease*).tw.
86. stroke*1.tw.
87. (acute coronary adj2 syndrome*).tw.
88. apoplexy.tw.
89. isch?emic heart disease*.tw.
90. or/76-89
91. 75 or 90
92. 50 and 56
93. 91 and 92
94. exp animals/ not humans.sh.
95. 93 not 94
96. (adolescent or children).tw. or child, preschool.sh.
97. 95 not 96
EMBASE (1947 to present)
1. autoimmune disease/
2. rheumatic disease/
3. rheumatoid arthritis/
4. psoriasis/
5. psoriatic arthritis/
6. polymyositis/
7. myositis/
8. polymyositis/
9. dermatomyositis/
10. systemic lupus erythematosus/
11. lupus erythematosus nephritis/
12. brain vasculitis/
13. multiple sclerosis/
14. Sjoegren syndrome/
15. bullous pemphigoid/
16. inflammatory bowel disease/
17. ulcerative colitis/
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18. Crohn disease/
19. myelitis/
20. exp systemic sclerosis/
21. myasthenia gravis/
22. ANCA associated vasculitis/
23. Churg Strauss syndrome/
24. microscopic polyangiitis/
25. Wegener granulomatosis/
26. polyarteritis nodosa/
27. aorta arch syndrome/
28. (autoimmune adj (disease* or disorder*)).tw.
29. (rheumatic adj (disease* or disorder*)).tw.
30. rheumatoid arthritis.tw.
31. psoriasis.tw.
32. psoriatic arthritis.tw.
33. polymyositis.tw.
34. dermatomyositis.tw.
35. (inflammatory adj2 myopath*).tw.
36. systemic lupus erythematosus.tw.
37. (SLE and lupus).tw.
38. multiple sclerosis.tw.
39. sjogren*.tw.
40. (bullous adj2 pemphigoid).tw.
41. inflammatory bowel disease*.tw.
42. (IBD and (inflammatory and bowel)).tw.
43. Crohn*.tw.
44. ulcerative colitis.tw.
45. transverse myelitis.tw.
46. systemic sclerosis.tw.
47. systemic scleroderma.tw.
48. myasthenia gravis.tw.
49. wegener* granulomatosis.tw.
50. microscopic polyangiitis.tw.
51. microscopic polyarteritis.tw.
52. (granulomatosis adj2 polyangiitis).tw.
53. allergic granulomatosis.tw.
54. eGPA.tw.
55. eosinophilic granulomatosis.tw.
56. churg strauss syndrome*.tw.
57. takayasu arteritis.tw.
58. (ANCA adj2 vasculitis).tw.
59. antineutrophil cytoplasmic antibody associated vasculitis.tw.
60. or/1-59
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61. methotrexate/
62. methotrexate.tw.
63. MTX.tw.
64. (abitrexate or amethopterine or ametopterine or antifolan or artrait or atrexel or
bendatrexat or biotrexate or carditrex or canceren or dermotrex or ebetrex or emtexate
or emthexat or emthexate or emtrexate or enthexate or farmitrexat or farmitrexate or
farmotrex or folex or ifamet or imeth or lantarel or ledertrexate or maxtrex or metex
or methoblastin or methohexate or methotrate or methotrexat or methotrexato or
methoxtrexate or methrotrexate or meticil or metoject or metothrexate or metotrexat
or metotrexate or metotrexin or metrex or mexate or mpi 5004 or mpi5004 or
neotrexate or novatrex or nsc 740 or nsc740 or otrexup or reumatrex or rheumatrex or
texate or texorate or trexall or trexan or xaken or zexate).tw.
65. amethopterin.tw.
66. or/61-65
67. mortality/
68. "cause of death"/
69. fatality/
70. premature mortality/
71. death/
72. exp sudden death/
73. life expectancy/
74. life table/
75. Vital Statistics/
76. vital statistics/
77. mortalit*.tw.
78. (death or dead or die or died or dies).tw.
79. ((hazard* or cox) adj2 (model* or regression*)).tw.
80. (sudden adj2 death).tw.
81. kaplan meier*.tw.
82. (life table* or lifetable*).tw.
83. or/67-82
84. exp cardiovascular disease/
85. exp cerebrovascular disease/
86. cardiovascular mortality/
87. (cardiac adj2 (event* or arrest* or failure)).tw.
88. (cardiovascular adj2 (disease* or event* or disorder*)).tw.
89. (cerebrovascular adj2 (disease* or event* or disorder* or accident*)).tw.
90. (myocardi* adj2 (infarct* or revascular* or isch?emi*)).tw.
91. (morbid* adj2 (heart* or coronar* or isch?em* or myocard*)).tw.
92. (heart adj (infarct* or arrest* or attack* or failure or event* or bypass*)).tw.
93. (coronary adj (disease* or event* or bypas* or graft*)).tw.
94. (coronary adj (heart or artery) adj disease*).tw.
95. stroke*1.tw.
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96. (acute coronary adj2 syndrome*).tw.
97. apoplexy.tw.
98. isch?emic heart disease*.tw.
99. or/84-98
100. 83 or 99
101. 60 and 66
102. 100 and 101
103. (animal$ not human$).sh,hw.
104. 102 not 103
105. exp pediatrics/
106. child/
107. adolescent/
108. (adolescent* or child* or preschool* or pre school*).tw.
109. or/105-108
110. 104 not 109
Web of Science
1. TS=(((autoimmune OR rheumatic) NEAR/1 disease*) OR rheumatoid arthritis OR
psoriasis OR polymyositis OR myositis OR "systemic lupus erythematosus" OR
"multiple sclerosis" OR sjogren* OR "bullous pemphigoid" OR dermatomyositis OR
(inflammatory NEAR/1 myopath*) OR ("inflammatory bowel" NEAR/1 disease*) or
crohn* or "ulcerative colitis")
DocType=All document types; Language=All languages;
2. TS=(methotrexate OR MTX OR abitrexate OR amethopterine OR ametopterine OR
antifolan OR artrait OR atrexel OR bendatrexat OR biotrexate OR carditrex OR
canceren OR dermotrex OR ebetrex OR emtexate OR emthexat OR emthexate OR
emtrexate OR enthexate OR farmitrexat OR farmitrexate OR farmotrex OR folex OR
ifamet OR imeth OR lantarel OR ledertrexate OR maxtrex OR metex OR
methoblastin OR methohexate OR methotrate OR methotrexat OR methotrexato OR
methoxtrexate OR methrotrexate OR meticil OR metoject OR metothrexate OR
metotrexat OR metotrexate OR metotrexin OR metrex OR mexate OR mpi 5004 OR
mpi5004 OR neotrexate OR novatrex OR nsc 740 OR nsc740 OR otrexup OR
reumatrex OR rheumatrex OR texate OR texorate OR trexall OR trexan OR xaken
OR zexate OR amethopterin)
DocType=All document types; Language=All languages;
3. (#2 AND #1)
DocType=All document types; Language=All languages;
4. TS=(mortalit* OR fatal* OR death OR dead OR die OR died OR dies OR "life table"
OR "life tables" OR lifetable* OR "hazard model" OR "kaplan meier" OR "cox
model")
DocType=All document types; Language=All languages;
5. TS=((cardiac NEAR/2 (event* OR arrest* OR failure)) OR ((cardiovascular OR
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cerebrovascular) NEAR/2 (disease* OR event* OR disorder* OR accident*)) OR
(myocardi* NEAR/2 (infarct* OR revascular* OR isch?em*)) OR (morbid* NEAR/2
(heart* OR coronar* OR isch?em* OR myocard*)) OR (heart NEAR/1 (infarct* OR
arrest* OR attack* OR failure OR event*)) OR (coronary NEAR/1 (disease* OR
event OR bypas* OR graft*)) OR coronary heart disease* OR coronary artery
disease* OR stroke OR strokes)
DocType=All document types; Language=All languages;
6. (#5 OR #4)
DocType=All document types; Language=All languages;
7. (#3 AND #6)
DocType=All document types; Language=All languages;
The Cochrane Library
1. MeSH descriptor: [Autoimmune Diseases] this term only
2. MeSH descriptor: [Rheumatic Diseases] this term only
3. MeSH descriptor: [Arthritis, Rheumatoid] this term only
4. MeSH descriptor: [Psoriasis] explode all trees
5. MeSH descriptor: [Myositis] this term only
6. MeSH descriptor: [Polymyositis] this term only
7. MeSH descriptor: [Dermatomyositis] this term only
8. MeSH descriptor: [Lupus Erythematosus, Systemic] 1 tree(s) exploded
9. MeSH descriptor: [Multiple Sclerosis] 1 tree(s) exploded
10. MeSH descriptor: [Sjogren's Syndrome] this term only
11. MeSH descriptor: [Pemphigoid, Bullous] this term only
12. MeSH descriptor: [Inflammatory Bowel Diseases] explode all trees
13. MeSH descriptor: [Myelitis, Transverse] 3 tree(s) exploded
14. MeSH descriptor: [Myasthenia Gravis] this term only
15. MeSH descriptor: [Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis] 1
tree(s) exploded
16. MeSH descriptor: [Polyarteritis Nodosa] this term only
17. MeSH descriptor: [Takayasu Arteritis] this term only
18. MeSH descriptor: [Scleroderma, Systemic] explode all trees
19. (AUTOIMMUNE near/2 (DISEASE* or DISORDER*)):ti,ab,kw
20. (RHEUMATIC near/2 (DISEASE* or DISORDER*)):ti,ab,kw
21. (RHEUMATOID next ARTHRITIS)
22. (PSORIASIS)
23. (PSORIATIC next ARTHRITIS)
24. (POLYMYOSITIS or DERMATOMYOSITIS)
25. (INFLAMMATORY near/2 MYOPATH*)
26. (SYSTEMIC next LUPUS next ERYTHEMATOSUS)
27. (SLE and LUPUS)
28. (MULTIPLE next SCLEROSIS)
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29. (SJOGREN*)
30. (BULLOUS near/2 PEMPHIGOID)
31. (INFLAMMATORY next BOWEL next DISEASE*)
32. (IBD and (INFLAMMATORY and BOWEL))
33. (CROHN*)
34. (ULCERATIVE next COLITIS)
35. (TRANSVERSE next MYELITIS)
36. (SYSTEMIC near/2 SCLEROSIS)
37. (SYSTEMIC near/2 SCLERODERMA)
38. (MYASTHENIA next GRAVIS)
39. (WEGENER* next GRANULOMATOSIS)
40. (MICROSCOPIC next POLYANGIITIS)
41. (MICROSCOPIC next POLYARTERITIS)
42. (GRANULOMATOSIS near/2 POLYANGIITIS)
43. (ALLERGIC next GRANULOMATOSIS)
44. (EGPA)
45. (EOSINOPHILIC next GRANULOMATOSIS)
46. (CHURG next STRAUSS next SYNDROME)
47. (ANCA near/2 VASCULITIS)
48. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14
or #15 or #16 or #17 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39
or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47)
49. MeSH descriptor: [Methotrexate] this term only
50. MeSH descriptor: [Aminopterin] this term only
51. (METHOTREXATE)
52. (AMINOPTERIN)
53. (MTX)
54. (ABITREXATE or AMETHOPTERIN or AMETHOPTERINE or AMETOPTERINE
or ANTIFOLAN or ARTRAIT or ATREXEL or BENDATREXAT or
BIOTREXATE or CARDITREX or CANCEREN or DERMOTREX or EBETREX
or EMTEXATE or EMTHEXAT or EMTHEXATE or EMTREXATE or
ENTHEXATE or FARMITREXAT or FARMITREXATE or FARMOTREX or
FOLEX or IFAMET or IMETH or LANTAREL or LEDERTREXATE or
MAXTREX or METEX or METHOBLASTIN or METHOHEXATE or
METHOTRATE or METHOTREXAT or METHOTREXATO or
METHOXTREXATE or METHROTREXATE or METICIL or METOJECT or
METOTHREXATE or METOTREXAT or METOTREXATE or METOTREXIN or
METREX or MEXATE or MPI 5004 or MPI5004 or NEOTREXATE or
NOVATREX or NSC 740 or NSC740 or OTREXUP or REUMATREX or
RHEUMATREX or TEXATE or TEXORATE or TREXALL or TREXAN or
XAKEN or ZEXATE)
55. (#49 or #50 or #51 or #52 or #53 or #54)
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56. (#48 and #55)
57. MeSH descriptor: [Mortality] this term only
58. MeSH descriptor: [Cause of Death] this term only
59. MeSH descriptor: [Fatal Outcome] this term only
60. MeSH descriptor: [Hospital Mortality] this term only
61. MeSH descriptor: [Mortality, Premature] this term only
62. MeSH descriptor: [Death] this term only
63. MeSH descriptor: [Death, Sudden] this term only
64. MeSH descriptor: [Death, Sudden, Cardiac] this term only
65. MeSH descriptor: [Death Certificates] this term only
66. MeSH descriptor: [Life Expectancy] this term only
67. MeSH descriptor: [Life Tables] this term only
68. MeSH descriptor: [Vital Statistics] this term only
69. ((HAZARD* or COX) near/2 MODEL*)
70. (SUDDEN near/2 DEATH)
71. (MORTALIT* or DIED or DIE or DEATH or DEAD)
72. (KAPLAN next MEIER*)
73. (LIFE next TABLE*) or (LIFETABLE*)
74. (#57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #65 or #66 or #67 or #68 or
#69 or #70 or #71 or #72 or #73)
75. MeSH descriptor: [Cardiovascular Diseases] explode all trees
76. MeSH descriptor: [Cerebrovascular Disorders] explode all trees
77. (CARDIAC near/2 (EVENT* or ARREST* or FAILURE))
78. (CARDIOVASCULAR near/2 (DISEASE* or EVENT* or DISORDER*))
79. (CEREBROVASCULAR near/2 (DISEASE* or EVENT* or DISORDER* or
ACCIDENT*))
80. (HEART near/2 (INFARCT* or ARREST* or DISEASE* or ATTACK* or
FAILURE or EVENT* or BYPAS*))
81. (CORONARY near/2 (DISEASE* or EVENT* or BYPAS* or GRAFT*))
82. (MYOCARDIAL* near/2 (INFARCT* or RE?VASCULAR* or ISCH?EMI*))
83. (MORBID* near (HEART* or CORONARY* or ISCH?EMI* or MYOCARD*))
84. (CORONARY next (DISEASE* or EVENT* or BYPAS* or GRAFT*))
85. (STROKE or STROKES)
86. (ISCH?EMIC next HEART next DISEASE*)
87. (APOPLEXY)
88. (#75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85 or #86 or
#87)
89. (#74 or #88)
90. (#56 and #89)
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Google scholar
Methotrexate AND “rheumatoid arthritis” AND (coronary OR cardiovascular OR
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
Methotrexate AND “Psoriasis” AND (coronary OR cardiovascular OR myocardial OR
ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR ischemia OR
vascular OR angina OR mortality OR morbidity OR death OR dead OR chd OR cad OR
ihd)
Methotrexate AND “Psoriatic arthritis” AND (coronary OR cardiovascular OR
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
Methotrexate AND “dermatomyositis” AND (coronary OR cardiovascular OR
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
Methotrexate AND “polymyositis” AND (coronary OR cardiovascular OR myocardial
OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR ischemia OR
vascular OR angina OR mortality OR morbidity OR death OR dead OR chd OR cad OR
ihd)
Methotrexate AND “systemic lupus erythematosus” AND (coronary OR cardiovascular
OR myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular
OR ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR
chd OR cad OR ihd)
Methotrexate AND “multiple sclerosis” AND (coronary OR cardiovascular OR
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
Methotrexate AND “Sjogren’s syndrome” AND (coronary OR cardiovascular OR
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
Methotrexate AND “bullous pemphigoid” AND (coronary OR cardiovascular OR
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myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
Methotrexate AND “crohn’s disease” AND (coronary OR cardiovascular OR myocardial
OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR ischemia OR
vascular OR angina OR mortality OR morbidity OR death OR dead OR chd OR cad OR
ihd)
Methotrexate AND “ulcerative colitis” AND (coronary OR cardiovascular OR
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
Methotrexate AND “transverse myelitis” AND (coronary OR cardiovascular OR
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
Methotrexate AND “systemic sclerosis” AND (coronary OR cardiovascular OR
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
Methotrexate AND “myasthenia gravis” AND (coronary OR cardiovascular OR
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
Methotrexate AND “Wegener’s granulomatosis” AND (coronary OR cardiovascular OR
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
Methotrexate AND “microscopic polyangitis” AND (coronary OR cardiovascular OR
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
Methotrexate AND “eosinophilic granulomatosis with polyangitis” AND (coronary OR
cardiovascular OR myocardial OR ischemic OR infarction OR infarct OR stroke OR
cerebrovascular OR ischemia OR vascular OR angina OR mortality OR morbidity OR
death OR dead OR chd OR cad OR ihd)
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Methotrexate AND “takayasu’s arteritis” AND (coronary OR cardiovascular OR
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
Methotrexate AND “ANCA” AND “vasculitis” AND (coronary OR cardiovascular OR
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd
OR cad OR ihd)
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Appendix C. Study Eligibility Assessment Form
Study No.:
Study title:
Last name of first author:
Reviewer’s Initial:

RefWorks ID:
Year of publication:

All criteria must met
1

Is the study published in English language?

Yes

No

2

Study design (Cohort, Case-control or RCT)

Yes

No

3

Did the study report any of the following events in its analysis
including adverse event (AE) analysis?
1. Cardiovascular events
2. Fatal/non-fatal MI
3. ACS/IHD/CAD
4. Sudden cardiac death
5. Heart failure
6. Cardiac arrest
7. Stroke
8. Hospitalization due to cardiac event
9. All-cause mortality
10. Cardiovascular mortality

Yes

No

4

Did the study report the association of MTX with any of the
outcomes listed above in its analysis including AE analysis?

Yes

No

5

Did the study produce an analysis (including AE analysis) that
compares the outcome of interest between MTX users versus
non-users or placebo group?

Yes

No

6

Did the study report any of the following statistical
measuresfor the association of MTX with the outcomes of
interest?
1. Number of patients experiencing event (n)
2. Incidence rates
3. Cumulative incidence
4. OR (95% CI)
5. RR (95% CI)
6. Risk ratio (95% CI)

Yes

No
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7

Did the study include patients with any of the following
autoimmune diseases?
1. Rheumatoid arthritis
2. Psoriasis
3. Psoriatic arthritis
4. Dermatomyositis
5. Polymyositis
6. Myositis
7. Systemic Lupus Erythematosus
8. Multiple sclerosis
9. Sjogren’s syndrome
10. Bullous pemphigoid
11. Crohn’s disease
12. Ulcerative colitis
13. Transverse Myelitis
14. Systemic sclerosis (Scleroderma)
15. Myasthenia Gravis
16. ANCA associated vasculitis
17. Takayasu’s arteritis

8

Additional comments ____________________________________

9

Reviewer's final assessment.
1. Include
2. Exclude
3. Unclear

10

Yes

Include
Exclude
Unclear

Reason for exclusion/unclear study_________________________

No
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Appendix D. Data Abstraction Form
1. Citation details
Study No.
RefWorks ID.
Data abstraction date
Abstracter’s initial
First author
Second author (if only two authors on the
study
Publication year
2. Study characteristics

Publication type

Full text
Abstract
Other (Specify) _______________

Country of study
Study design
Data collection
Study setting
Accrual start date (dd/mm/yyyy)
Accrual end date (dd/mm/yyyy)
Follow start date (dd/mm/yyyy)
Follow end date (dd/mm/yyyy)
Total follow up period (months)
Inclusion criteria
Exclusion criteria
Source of information for study sample

Randomized Controlled Trial (RCT)
Case-control
Cohort
Prospective
Retrospective
Hospital based
Out-patient
Unclear
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3. Additional information for RCT

Trial design

Parallel
Cross-over
Factorial
Other (Specify) _______________

Treatment arms
4. Characteristics of underling disease
Disease
Diagnostic criteria
Disease duration
(mean, SD, median IQR, range)
Severity of underlying disease
5. Sample characteristics
Sample size (cohort )
Sample size (cases or MTX group)
Sample size (controls or non-MTX group)
Age (cohort) (mean, SD, median, IQR)
Age (cases or MTX group)
(mean, SD, median, IQR)
Age (controls or non-MTX group)
% Female or Gender (cohort)
% Female (cases or MTX group)
% Female (controls or non-MTX group)
% with baseline CVD (cohort)
% with baseline CVD (cases or MTX group)
% with baseline CVD (controls or non-MTX
group)
Does the sample contain patients with RA?

Yes
No

6. Exposure characteristics (MTX)
MTX exposure definition
Dose of MTX reported
Dose in mg/week (mean, median, SD)

Yes
No
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Duration of MTX use
(months) (mean, median, SD)
Initiators vs. non-initiators
Ever-users vs. never-users
Current-users vs. non-current users
Unclear

Exposure type

Data source of MTX exposure
7. Outcome characteristics
Outcome

Definition

Data source

1.
2.
3.
Did the study report any of the CVD or
mortality outcomes as adverse event?
Did the study exclude patients with prior or
current CVD in analysis?

Yes
No
Yes
No

8. Analysis and results
Total observation time
(mean-SD, median- range)
Person-years or months exposure of whole
cohort

Outcome of
interest

Personyears
exposure
for
particular
outcome

Events in
cohort

Events in
cases or
MTX
group

Events
in
control
group

Sample
size
(cohort)
(n)

Sample
size
(cases or
MTX
group)
(n2)

Sample
size
(control
or nonMTX
group)
(n3)
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Outcome of
interest

Effect
measures
(RR, OR,
HR, rate
ratio,
IRR)

Adjusted
effect
estimate
(MTX vs.
no-MTX)

95% CI of
adjusted
estimate
(MTX vs.
no-MTX)

p-value
of
adjusted
estimate
(MTX
vs. noMTX)

Adjusted
variables
in the
analysis

Did the analysis include MTX as timevarying covariate?
List all other time varying covariates in the
model

Methods
used to
adjust
confounding

Source of
outcome in
article
1. Page #
2. Table #
3. Fig.#

Yes
No

9. Subgroup analysis

Subgroups

Operational
definition

Adjusted
effect
estimate
(MTX vs.
no-MTX)

95% CI of
adjusted
estimate
(MTX vs.
no-MTX)

p-value
of
adjusted
estimate
(MTX
vs. noMTX)

Adjusted
variables
in the
analysis

Formal
test of
interaction

Source of
outcome
in article
1. Page #
2. Table #
3. Fig.#

Adjusted
variables
in the
analysis

Source of
outcome
(article)
1.page #
2. Table #
3. Fig.#:

10. Dose response analysis

MTX dose group

Definition

Adjusted
effect
estimate
(MTX vs. noMTX)

95% CI of
adjusted
estimate
(MTX vs. noMTX)

p-value of
adjusted
estimate
(MTX vs.
no-MTX)
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11. Additional comment
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Appendix E. Newcastle-Ottawa Quality Assessment Scale
CASE CONTROL STUDIES
Note: A study can be awarded a maximum of one star for each numbered item within the
Selection and Exposure categories. A maximum of two stars can be given for
Comparability.
Selection
1) Is the case definition adequate?
a) Yes, with independent validation *
b) Yes, e.g. record linkage or based on self-reports
c) No description
2) Representativeness of the cases
a) Consecutive or obviously representative series of cases *
a) Potential for selection biases or not stated
3) Selection of Controls
a) Community controls *
b) Hospital controls
c) No description
4) Definition of Controls
a) No history of disease (endpoint) *
b) No description of source
Comparability
1) Comparability of cases and controls on the basis of the design or analysis
a) Study controls for _______________ (Select the most important factor) *
b) Study controls for any additional factor (This criteria could be modified to
indicate specific control for a second important factor)
Exposure
1) Ascertainment of exposure
a) Secure record (e.g. surgical records) *
b) Structured interview where blind to case/control status *
c) Interview not blinded to case/control status
d) Written self-report or medical record only
e) No description
2) Same method of ascertainment for cases and controls
a) Yes *
b) No
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3) Non-Response rate
a) Same rate for both groups *
b) Non respondents described
c) Rate different and no designation
COHORT STUDIES
Note: A study can be awarded a maximum of one star for each numbered item within the
Selection and Outcome categories. A maximum of two stars can be given for
Comparability
Selection
1) Representativeness of the exposed cohort
a) Truly representative of the average _______________ (describe) in the
community *
b) Somewhat representative of the average ______________ in the community *
c) Selected group of users e.g. nurses, volunteers
d) No description of the derivation of the cohort
2) Selection of the non-exposed cohort
a) Drawn from the same community as the exposed cohort *
b) Drawn from a different source
c) No description of the derivation of the non-exposed cohort
3) Ascertainment of exposure
a) Secure record (e.g. surgical records) *
b) Structured interview *
c) Written self-report
d) No description
4) Demonstration that outcome of interest was not present at start of study
a) Yes *
b) No
Comparability
1) Comparability of cohorts on the basis of the design or analysis
a) Study controls for _____________ (select the most important factor) *
b) Study controls for any additional factor * (This criteria could be modified to
indicate specific control for a second important factor)
Outcome
1) Assessment of outcome
a) Independent blind assessment *
b) Record linkage *
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c) Self-report
d) No description

2) Was follow-up long enough for outcomes to occur
a) Yes (select an adequate follow up period for outcome of interest) *
b) No
3) Adequacy of follow up of cohorts
a) Complete follow up - all subjects accounted for *
b) Subjects lost to follow up unlikely to introduce bias - small number lost - > ____
% (select an adequate %) follow up, or description provided of those lost) *
c) Follow up rate < ____% (select an adequate %) and no description of those lost
d) No statement
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Appendix F. The Cochrane Collaboration’s tool for assessing risk of bias
Domain
Sequence generation

Allocation concealment

Blinding of participants, personnel
and outcome assessors Assessments
should be made for each main
outcome (or class of outcomes)
Incomplete outcome data
Assessments should be made for each
main outcome (or class of outcomes)

Selective outcome reporting

Other sources of bias

Description
Describe the method used to generate the allocation sequence in
sufficient detail to allow an assessment of whether it should produce
comparable groups.
Describe the method used to conceal the allocation sequence in
sufficient detail to determine whether intervention allocations could
have been foreseen in advance of, or during, enrolment.
Describe all measures used, if any, to blind study participants and
personnel from knowledge of which intervention a participant
received. Provide any information relating to whether the intended
blinding was effective.
Describe the completeness of outcome data for each main outcome,
including attrition and exclusions from the analysis. State whether
attrition and exclusions were reported, the numbers in each
intervention group (compared with total randomized participants),
reasons for attrition/exclusions where reported, and any re-inclusions
in analyses performed by the review authors.
State how the possibility of selective outcome reporting was
examined by the review authors, and what was found.
State any important concerns about bias not addressed in the other
domains in the tool. If particular questions/entries were pre-specified
in the review’s protocol, responses should be provided for each
question/entry.

Review authors’ judgement
Was the allocation sequence
adequately generated?
Was allocation adequately
concealed?
Was knowledge of the allocated
intervention adequately prevented
during the study?
Were incomplete outcome data
adequately addressed?

Are reports of the study free of
suggestion of selective outcome
reporting?
Was the study apparently free of
other problems that could put it at
a high risk of bias?

Possible approach for summary assessments outcome (across domains) within and across studies
Risk of bias
Low risk of bias

Interpretation
Plausible bias unlikely to

Within a study
Low risk of bias for all key

Across studies
Most information is from studies at low risk
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Unclear risk of bias
High risk of bias

seriously alter the results.
Plausible bias that raises some
doubt about the results
Plausible bias that seriously
weakens confidence in the results.

domains.
Unclear risk of bias for one or
more key domains.
High risk of bias for one or more
key domains.

of bias.
Most information is from studies at low or
unclear risk of bias.
The proportion of information from studies at
high risk of bias is sufficient to affect the
interpretation of the results.

Criteria for judging risk of bias in the ‘Risk of bias’ assessment tool
SEQUENCE GENERATION
Was the allocation sequence adequately generated? [Short form: Adequate sequence generation?]
Criteria for a judgement of ‘YES’ The investigators describe a random component in the sequence generation process such as:
(i.e. low risk of bias).
 Referring to a random number table; Using a computer random number generator; Coin tossing; Shuffling
cards or envelopes; Throwing dice; Drawing of lots; Minimization*.
*Minimization may be implemented without a random element, and this is considered to be equivalent to being
random.
Criteria for the judgement of ‘NO’ The investigators describe a non-random component in the sequence generation process. Usually, the description
(i.e. high risk of bias).
would involve some systematic, non-random approach, for example:
 Sequence generated by odd or even date of birth;
 Sequence generated by some rule based on date (or day) of admission;
 Sequence generated by some rule based on hospital or clinic record number.
Other non-random approaches happen much less frequently than the systematic approaches mentioned above and
tend to be obvious. They usually involve judgement or some method of non-random categorization of
participants, for example:
 Allocation by judgement of the clinician;
 Allocation by preference of the participant;
 Allocation based on the results of a laboratory test or a series of tests;
 Allocation by availability of the intervention.
Criteria for the judgment of
Insufficient information about the sequence generation process to permit judgement of ‘Yes’ or ‘No’.
‘UNCLEAR’ (uncertain risk of
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bias).
ALLOCATION CONCEALMENT
Was allocation adequately concealed? [Short form: Allocation concealment?]
Criteria for a judgement of
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an
‘YES’ (i.e. low risk of bias).
equivalent method, was used to conceal allocation:
 Central allocation (including telephone, web-based, and pharmacy-controlled, randomization);
 Sequentially numbered drug containers of identical appearance;
 Sequentially numbered opaque, sealed envelopes.
Criteria for the judgement of
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection
‘NO’ (i.e. high risk of bias).
bias, such as allocation based on:
 Using an open random allocation schedule (e.g. a list of random numbers);
 Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque
or not sequentially numbered);
 Alternation or rotation;
 Date of birth;
 Case record number;
 Any other explicitly unconcealed procedure.
Criteria for the judgement of
Insufficient information to permit judgement of ‘Yes’ or ‘No’. This is usually the case if the method of concealment
‘UNCLEAR’ (uncertain risk of is not described or not described in sufficient detail to allow a definite judgement – for example if the use of
bias).
assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque
and sealed..
BLINDING OF PARTICIPANTS, PERSONNEL AND OUTCOME ASSESSORS
Was knowledge of the allocated interventions adequately prevented during the study? [Short form: Blinding?]
Criteria for a judgement of
Any one of the following:
‘YES’ (i.e. low risk of bias).
 No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be
influenced by lack of blinding;
 Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken;
 Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the
non-blinding of others unlikely to introduce bias.
Criteria for the judgement of
Any one of the following:
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‘NO’ (i.e. high risk of bias).



No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack
of blinding;
 Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken;
 Either participants or some key study personnel were not blinded, and the non-blinding of others likely to
introduce bias.
Criteria for the judgement of
Any one of the following:
‘UNCLEAR’ (uncertain risk of  Insufficient information to permit judgement of ‘Yes’ or ‘No’;
bias).
 The study did not address this outcome.
INCOMPLETE OUTCOME DATA
Were incomplete outcome data adequately addressed? [Short form: Incomplete outcome data addressed?]
Criteria for a judgement of
Any one of the following:
‘YES’ (i.e. low risk of bias).
 No missing outcome data;
 Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to
be introducing bias);
 Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data
across groups;
 For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not
enough to have a clinically relevant impact on the intervention effect estimate;
 For continuous outcome data, plausible effect size (difference in means or standardized difference in means)
among missing outcomes not enough to have a clinically relevant impact on observed effect size;
 Missing data have been imputed using appropriate methods.
Criteria for the judgement of
Any one of the following:
‘NO’ (i.e. high risk of bias).
 Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or
reasons for missing data across intervention groups;
 For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough
to induce clinically relevant bias in intervention effect estimate;
 For continuous outcome data, plausible effect size (difference in means or standardized difference in means)
among missing outcomes enough to induce clinically relevant bias in observed effect size;
 ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at
randomization;

98

 Potentially inappropriate application of simple imputation.
Any one of the following:
 Insufficient reporting of attrition/exclusions to permit judgement of ‘Yes’ or ‘No’ (e.g. number randomized not
stated, no reasons for missing data provided);
 The study did not address this outcome.
SELECTIVE OUTCOME REPORTING
Are reports of the study free of suggestion of selective outcome reporting? [Short form: Free of selective reporting?]
Criteria for a judgement of
Any of the following:
‘YES’ (i.e. low risk of bias).
 The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
 The study protocol is not available but it is clear that the published reports include all expected outcomes,
including those that were pre-specified (convincing text of this nature may be uncommon).
Criteria for the judgement of
Any one of the following:
‘NO’ (i.e. high risk of bias).
 Not all of the study’s pre-specified primary outcomes have been reported;
 One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g.
subscales) that were not pre-specified;
 One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is
provided, such as an unexpected adverse effect);
 One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a
meta-analysis;
 The study report fails to include results for a key outcome that would be expected to have been reported for such
a study.
Criteria for the judgement of
Insufficient information to permit judgement of ‘Yes’ or ‘No’. It is likely that the majority of studies will fall into
‘UNCLEAR’ (uncertain risk of this category.
bias).
OTHER POTENTIAL THREATS TO VALIDITY
Was the study apparently free of other problems that could put it at a risk of bias? [Short form: Free of other bias?]
Criteria for a judgement of
The study appears to be free of other sources of bias.
‘YES’ (i.e. low risk of bias).
Criteria for the judgement of
There is at least one important risk of bias. For example, the study:
Criteria for the judgement of
‘UNCLEAR’ (uncertain risk of
bias).
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‘NO’ (i.e. high risk of bias).

Criteria for the judgement of
‘UNCLEAR’ (uncertain risk of
bias).

 Had a potential source of bias related to the specific study design used; or
 Stopped early due to some data-dependent process (including a formal-stopping rule); or
 Had extreme baseline imbalance; or
 Has been claimed to have been fraudulent; or
 Had some other problem.
There may be a risk of bias, but there is either:
 Insufficient information to assess whether an important risk of bias exists; or
 Insufficient rationale or evidence that an identified problem will introduce bias.
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Appendix G. Characteristics of included studies
Accrual
period

Sample
size

Better Anti-Rheumatic
Pharmaco Therapy
(BARFOT) (Sweden)

1993-1999

741

RA

Protocare longitudinal health
benefit claims database and
PharMetrics Integrated
Outcomes Database
(North America)

1998-2001

5720

Retrospective
cohort

RA

Medical Centers, Danville,
PA, USA

2001-2008

1829

Chiang et al., 201366

Retrospective
cohort

Systemic
sclerosis
(SSc)

Longitudinal Health Insurance
Database2005, Taiwan

1997-2006

1238

Chin et al., 201367

Retrospective
cohort

Psoriasis,
psoriatic arthritis
(PsA)

Longitudinal Health Insurance
Database 2005, Taiwan

1997-2006

7932

Choi et al., 2002113

Prospective
cohort

RA

Wichita Arthritis Center,
USA

1981-1999

1240

RCT

RA

Multicenter,
North America

Not
specified

318

Study
Ajeganova et al., 201363

Bernatsky et al., 2005

64

Bozaite-Gluosniene et
al.,201165

Cohen et al., 2001114

Design

Disease studied

Prospective
cohort

RA

Nested
Case-control

Setting/Data source

Inclusion criteria
(Exclusion criteria)
RA patients according to ACR criteria, age ≥18
years, disease duration ≤12 months
(Patients with prevalent CVD at the time of RA
diagnosis)
RA patients, age ≥18 years, without history of
CHF at the time of database entry, to have >3
months of eligibility in the health insurance
plan prior to main cohort entry
Cases: RA with CHF (ICD-9, code 428),
Controls: RA without CHF
RA patients without pre-existing CAD
SSc patients (ICD-9-CM, code 710.1), age ≥18
years at the time of SSc diagnosis, without prior
history of cerebrovascular disease
Newly diagnosed psoriasis patients (ICD-9,
code without arthritis: 696.1, 696.8, with
arthritis: 696.0), born between 1930 and 1990
(Patients with severe vascular disease prior to
psoriasis diagnosis, patients received both MTX
and retinoid)
RA patients fulfilling the 1958-1987 ACR
criteria, age ≥18 years, without use of MTX
before their first visit to the Center
(Patients with contraindications for MTX use)
RA patients diagnosed by ACR criteria for ≥6
months, age 18-75 years, not previously
received MTX, and could not have been
receiving other DMARDs for ≥30 days prior to
trial entry
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Study
Davis et al., 201375
Edwards et al., 200868
Gonzalez-Gay et al.,
2007116
Goodson et al., 2008111

Design

Disease studied

Prospective
cohort

RA

Retrospective
cohort

RA

Prospective
cohort

RA

Prospective
cohort

Inflammatory
polyarthritis

Lan et al., 201269

Retrospective
cohort

Levesque et al., 2013131

Setting/Data source
Veterans Affairs RA
(VARA) registry,
Veterans Affairs
medical centers, USA
The UK General Practice
Research Database (GPRD)
Rheumatology
outpatient clinic of
Hospital Xeral-Calde,
Lugo, Spain
The UK Norfolk Arthritis
Register (NOAR), UK

Accrual
period

Sample
size

Inclusion criteria
(Exclusion criteria)

2003unclear end
date

1047

RA patients meeting 1987 ACR criteria and
available for genotyping data for MTHER
C677T and/or A1298C polymorphisms

1987-2002

34364

Adult patients with RA

Mar 1996Sept 1996

182

RA patients diagnosed as per ACR 1987
criteria, consecutive unselected patients
attending OPD between Mar-Sep 1996

1990-1994

923

Patients with Inflammatory Polyarthritis (IP)

8180

Psoriasis patients(ICD-9 696.0, 696.1, 696.8),
born between 1930 and 1990
(patients with CVD before their first psoriasis
diagnosis)

Psoriasis

Longitudinal Health Insurance
Database 2005, Taiwan

Retrospective
cohort

Psoriasis

RAMQ database, The public
health plan, Province of
Quebec, Canada

2005-2010

5157

Mantel et al., 2014110

Nested casecontrol

RA

Epidemiological Investigation
of Rheumatoid Arthritis
(EIRA) study, Sweden

Not
specified

533

Meek et al., 201470

Prospective
cohort

2009-2011

480

RA patients, diagnosed by attending
rheumatologist, without prior CVD and
completed the CV screening protocol

Mikuls et al., 2011132

Prospective
cohort

1015

RA patients meeting 1987 ACR criteria, RA
onset > 18 years of age (Women and RA
patients with limited follow-up data)

RA

RA

The Arthritis Center Twente
Cardiovascular Disease(ACTCVD) project, The
Netherlands
Veterans Affairs
Rheumatoid Arthritis
(VARA) registry, USA

1997-2006

2002-2009

Newly diagnosed psoriasis patients between
2005-2010, age ≥20 years and used
phototherapy, oral or injectable psoriasis
treatment
Cases: RA patients experienced ACS following
RA diagnosis.
Controls: RA patients without ACS and
matched with cases for sex, year of diagnosis
and EIRA center
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Study
Myasoedova et al.,
201171

Nadareishvili et al.,
2008103
Norton et al., 2014107

Pope et al., 2001115

Prodanowich et al.,
2005108

Suissa et al., 2006133

Tisseverasinghe et al.,
2009118

Design

Disease studied

Setting/Data source

RA

Rochester Epidemiology
Project (REP) medical
records linkage system,
Minnesota, USA

Nested
case-control

RA

National Database for
Rheumatic Diseases (NDB),
USA

Retrospective
cohort

RA

32 rheumatology centres in the
UK

RCT

Systemic
sclerosis
(SSc)

Retrospective
cohort

Retrospective
cohort

RA, psoriasis

Nested
case-control

RA

Nested
case-control

Dermatomyositi
s,polymyositis

Multicenter, North America

Veterans Health
Administration Data Source,
Miami, Florida, USA

Accrual
period

Sample
size

1980-2008

795

Incident RA patients meeting 1987 ACR
criteria, age ≥18 years
(patients with personal history of heart failure)

Not
specified

832

RA diagnosed by rheumatologist
Cases: RA with Ischemic stroke
Controls: RA without stroke
(Cases with Intracerebral, subarachnoid,
subdural, epidural hemorrhages, TIA)

1986-2012

2763

DMARD naïve RA patients

Not
specified

71

1998-2003

Psoriasis
: 7615
RA:
6707
(total:
14322)

PharMetrics Patient-Centric
Outcomes Database, Insurance
claims database,
North America

1999-2003

6138

Quebec provincial physician
billing, hospitalization, and
pharmacy database, Canada

1994-2003

411

Inclusion criteria
(Exclusion criteria)

SSc patients, age ≥18 years, diagnosed SSc
within the past three years of study entry
(Overlap syndrome, mixed CTD, morphea,
linear scleroderma, contraindications to MTX
treatment, current or past use of MTX)
Patients with psoriasis (ICD-9, code 696.1) or
RA (ICD-9 code 714.0) or both diagnosis
(Vascular diagnosis before the diagnosis of RA
or psoriasis, MTX prescription after the
diagnosis of vascular disease)
RA patients (ICD-9, code 714.0), age ≥18, no
prior history of MI
Cases: RA with AMI hospitalization (ICD-9,
code 410)
Controls: RA without AMI
Patients with DM or PM (ICD-9: 710.3-710.4)
Cases: DM/PM with thrombotic event,
Controls: DM/PM without thrombotic event
(Patients with thrombotic events prior to the
diagnosis of DM or PM)
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Study
Troelsen et al., 2007120
van den Hoogen et al.,
1996106

van Halm et al., 2006117

Design

Disease studied

Prospective
cohort

RA

RCT

Systemic
sclerosis
(SSc)

Setting/Data source
Clinical sites in Denmark
Multicenter trial,
The Netherlands
Jan van Breemen Institute, an
outpatient clinic in
Amsterdam,
The Netherlands
10 rheumatology practices,
North America

Accrual
period

Sample
size

1995-1998

229

Not
specified

29

Not
specified

613

1981-2005

5626

Case-control

RA

Prospective
cohort

RA

Nested
case-control

RA

National Databank for
Rheumatic Diseases (NDB)
longitudinal Study, USA

Not
specified

9153

Wolfe et al., 2003134

Retrospective
cohort

RA

Wichita Arthritis Center, an
outpatient rheumatology
clinic, USA

1981-1999

1387

Wu et al., 2012109

Retrospective
cohort

Psoriasis,
psoriatic arthritis

Kaiser Permanente Southern
California (KPSC) health plan,
USA

2004-2010

8845

Wasko et al., 2013119
Wolfe and Michaud,
2008112

Inclusion criteria
(Exclusion criteria)
RA patients meeting ACR 1987 criteria
SSc patients meeting American Rheumatism
Association criteria, disease duration <3 years
(age<16 years, presence of other CTD,
contraindications to MTX use)
RA patients fulfilling ACR criteria, without
prior CV event
Cases: RA with first CV event
Controls: RA without CV event
RA patients fulfilling ACR 1987 criteria, age
≥18 years
RA diagnosed by rheumatologist
Cases: RA with incident myocardial infarction
(MI)
Controls: RA without MI
RA patients fulfilling 1958 or 1987 ACR
criteria
(patients not seen for 2 years of their death)
Psoriasis (ICD-9-CM code 696.1) or psoriatic
arthritis (ICD-9-CM code 696.0)
(prior history of MI (ICD-9-CM code 410.XX
or 412))

Abbreviations: ACR: American College of Rheumatology, CHF: Congestive heart failure, CAD: Coronary artery disease, ICD: International Classification of
Disease, MTX: Methotrexate, RCT: Randomized Controlled Trial, ACS: Acute coronary syndrome, TIA: Transient ischemic attack, DMARD: Disease
Modifying Anti-Rheumatic Drugs, CTD: Connective tissue disease, AMI: Acute myocardial infarction, DM: Dermatomyositis, PM: Polymyositis
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Appendix H. Characteristics of disease in each study
Study
Ajeganova et al., 2013
Bernatsky et al., 2005
Bozaite-Gluosniene et al.,2011
Chiang et al., 2013
Chin et al., 2013

Disease under study
RA
RA
RA
Systemic sclerosis
Psoriasis,
psoriatic arthritis

Diagnostic criteria
ACR criteria
Patients with ICD-9, code 714
Diagnosed by treating physician
Patients with ICD-9-CM code 710.1
Patients with ICD-9 code 696.1,
696.8, and 696.0

Choi et al., 2002

RA

1958-1987 ACR criteria

Cohen et al., 2001

RA

ACR criteria

Davis et al., 2013

RA

1987 ACR criteria

Edwards et al., 2008

RA

Criteria not specified

Gonzalez-Gay et al., 2007

RA

1987 ACR criteria

Goodson et al., 2008

Inflammatory
polyarthritis

Lan et al., 2012

Psoriasis

Levesque et al., 2013

Psoriasis

Patients with polymyositis
and Dermatomyositis
Patients with ICD-9 code
696.0, 696.1, 696.8
Newly diagnosed patients,
Criteria not specified
Not specified
Diagnosed by attending
Rheumatologist

Mantel et al., 2014

RA

Meek et al., 2014

RA

Mikuls et al., 2011

RA

1987 ACR criteria

Myasoedova et al., 2011

RA

Nadareishvili et al., 2008

RA

Norton et al., 2014

RA

1987 ACR criteria
Diagnosed by treating
Rheumatologist
Not specified
ACR preliminary criteria
for Scleroderma

Pope et al., 2001

Systemic sclerosis

Disease duration
≤ 12 months
Not specified
Not specified
Not specified
Newly diagnosed
Patients
Mean (SD):
9.0 (9.4) years
Mean 6.5 years
Mean (SD):
14.5 (12.2) years
Not specified
Mean, Median (IQR):
10.5, 8, (4-14) years
Not specified
Not specified
Not specified
Not specified
Median (IQR):
4.2 (1.5-11.3) years
Mean (SD):
12 (12) years
Not specified
Mean (SD):
15.9 (13.5) years
Not specified
Mean (SEM) months: 6.3 (1.0) (MTX), 7.3
(1.1) (placebo)
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Study
Prodanowich et al., 2005
Suissa et al., 2006

Disease under study
RA, psoriasis

Troelsen et al., 2007

RA
Dermatomyositis,
Polymyositis
RA

van den Hoogen et al., 1996

Systemic sclerosis

Tisseverasinghe et al., 2009

Diagnostic criteria
Patients with ICD-9 code 696.1 for psoriasis or
ICD-9 code 714.0 for RA
Patients with ICD-9 code 714.0
Patients with ICD-9 codes
710.3-710.4
1987 ACR criteria
American Rheumatism
Association criteria

van Halm et al., 2006

RA

ACR criteria

Wasko et al., 2013

RA

1987 ACR criteria

Wolfe and Michaud, 2008
Wolfe et al., 2003
Wu et al., 2012

RA
RA
Psoriasis,
psoriatic arthritis

Diagnosed by treating rheumatologist
1958 or 1987 ACR criteria

Disease duration
Not specified
Not specified
Not specified
Median (range): 6.3 (0.1-54) years
Mean (SD):
3.2 (6.3) years
Median
Cases: 7.7 years
Controls: 10.6 y.
Mean (SD):
10.58 (10.26) years
Median: 12.2 years
Mean (SD): 7.06 (8.52) years

ICD-9-CM code 696.1, 696.0

Abbreviations: RA: Rheumatoid arthritis, ACR: American College of Rheumatology, ICD: International Classification of Diseases

Not specified
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Appendix I. Exposure characteristics
Study
Ajeganova et al., 2013

Data source of MTX exposure
Better Anti-Rheumatic
Pharmaco Therapy registry

Bernatsky et al., 2005

Insurance claim database

Bozaite-Gluosniene et al.,2011

Medical records

Chiang et al., 2013
Chin et al., 2013

Longitudinal Health Insurance
Database (LHID2000), Taiwan
Longitudinal Health Insurance
Database (LHID2000), Taiwan

Choi et al., 2002

Wichita Arthritis Center medical
records, USA

Cohen et al., 2001

Medical records

Davis et al., 2013

VARA clinical database, USA

Edwards et al., 2008
Gonzalez-Gay et al., 2007
Goodson et al., 2008
Lan et al., 2012
Levesque et al., 2013

General Practice Research Database,
UK
Medical records,
Rheumatology clinic, Spain
Medical records,
UK Norfolk Arthritis Register
Longitudinal Health Insurance
Database 2005, Taiwan
RAMQ Health plan database,
Canada

MTX Exposure
Ever-users vs. never-users
(67.2% MTX users)
Current-users vs. non-users
MTX users: cases (29%), controls
(36%)
Ever-users vs. never-users
Ever users: 61%
Never users: 39%

Exposure definition
Regular use: >6 months during observation period
A prescription dispensed during the 45 days period
prior to the outcome (CHF)
Time-varying use of MTX, medication start and stop
date before CAD diagnosis or censor date

Ever-users vs. never-users

> 6 months of therapy before reaching primary
endpoint, death, or end of follow-up

Ever-users vs. never-users

Prescription drug claims of MTX

Initiators vs. non-initiators
(mean dose 13 mg per week
maximum dose 25 mg per week)
Initiators vs. placebo
Dose: 15 to 17.5 or 20 mg/week.
Initiators vs. non-initiators
MTX initiators: 51.2%

Once a patient starts MTX therapy, he or she was
considered on therapy for the rest of the follow-up
(intension-to-treat approach)
MTX naïve patients were randomized to MTX or
placebo

Ever-users vs. never-users
Ever-users vs. never-users
Current-users vs. never-users
MTX users: 23%
Ever-users vs. never-users
Ever-users vs. never-users
MTX users: 23.7%

MTX exposure at the time of study enrollment (yes/no)
Prescription of DMARDs compared to no prescription
during study period
Medication prescribed at study start and changes noted
during follow-up period
Current medication was recorded annually for 6 years
& then every 2-3 years,
Time-varying use of MTX in analysis
Prescription claims of MTX were identified from the
database
Treatment identified from the database
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Study

Nadareishvili et al., 2008
Norton et al., 2014
Pope et al., 2001

Data source of MTX exposure
Medical charts, patient register,
National Prescribed Drug Register
Medical records, The Arthritis
Center Twente, The Netherlands
Medical records, VARA registry
USA
Medical records, REP medical
record linkage system, USA
Patient self-report in questionnaire
Medical records
Medical records

Prodanowich et al., 2005

Computerized medical records

Suissa et al., 2006

Dispensed prescription data

Tisseverasinghe et al., 2009

Pharmacy database and physician
billing data

Troelsen et al., 2007

Medical charts

van den Hoogen et al., 1996

Medical records

van Halm et al., 2006

Medical records

Wasko et al., 2013

Patient self-report in semi-annual
questionnaire

Current-users vs. non-users

Wolfe and Michaud, 2008

Patient self-report in questionnaire

Current-users vs. never-users,
Average MTX dose: 14mg/week

Wolfe et al., 2003

Medical records

Ever-users vs. never-users

Wu et al., 2012

KPSC pharmacy database

Ever-users vs. never-users

Mantel et al., 2014
Meek et al., 2014
Mikuls et al., 2011
Myasoedova et al., 2011

MTX Exposure

Exposure definition

Unclear

MTX use in cases and controls was identified

Initiators vs. non-initiators
MTX: 60.6%

Baseline MTX users at study start

Current-users vs. never-users
Current users vs. never-users
Initiators vs. non-initiators
Initiators vs. non-initiators
Initiators vs. Placebo
Ever-users vs. never-users
Current users vs. non-current
users
Ever-users vs. never-users
MTX: 26.3%
Current users vs. non-current
users, MTX: 81% patients
Initiators vs. placebo
Ever-users vs. never-users,
MTX (Cases): 72%
MTX (controls): 44%

MTX use at baseline and follow-up visits, analyzed as a
time-varying use
Time-dependent variable represented the time each
patient was taking medication
Baseline use of MTX reported by patients
Time-varying use of MTX in DMARD naïve patients
Patients were randomized to MTX or placebo treatment
MTX prescriptions vs. no-MTX prescriptions before the
development of vascular disease
Prescription dispensed during the 30-day period prior to
the AMI in cases
≥ 1 prescription for the given drug, any time between
cohort entry and index date
Use of MTX reported in clinical charts
Patients were randomized to MTX and placebo
Medication use was identified either as monotherapy or
in combinations
MTX use was assessed as time-varying variable in the
analysis
Patients receiving MTX within 6 months prior to their
first MI
MTX use was assessed as time-varying variable in the
analysis
The date of the first dispensation of any non–TNF
inhibitor systemic agent after the third psoriasis
diagnosis

Abbreviations: CHF: Congestive heart failure, VARA: Veterans Affairs Rheumatoid Arthritis, REP: Rochester Epidemiology Project, AMI: acute myocardial
infarction, KPSC: Kaiser Permanente Southern California
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Appendix J. Outcome characteristics
Study

Data source of outcomes

Ajeganova et al., 2013

Swedish Hospital Discharge
Registry
National Cause of Death
Registry, Sweden

Bernatsky et al., 2005

Hospitalization records

Bozaite-Gluosniene et
al.,2011

Medical center records

Chiang et al., 2013

Insurance claim database,
Hospital records, outpatient visit
records, prescriptions claims for
stroke medications

Chin et al., 2013

Physician claims

Choi et al., 2002
Cohen et al., 2001

Medical records, Death
certificates, National Death
Index, USA
Medical records

Outcome

CVD
All-cause mortality

CHF requiring
hospitalization
Coronary artery disease
Cardiac revascularization
procedure

Definition

First ever CVD (ICD-9 and ICD-10 codes for
CVD: 410, 411, 413, 427F, 433-436, 440-444,
3066-3067, 3080, 3092, 3105, 3127, 3141, 3158,
88, 0961-0964, I20-21, Y832, I46, I63-I66, G45,
I70-I72, I73.9, and I74),
Mortality regardless of cause
First ever hospitalization due to
CHF (ICD-9 code 428)

Excluded patients
with prior or
current CVD

Yes

No

First ever CAD
(ICD-9 code 410-419.99)

Yes

Ischemic stroke

ICD-9-CM codes 433 - 435

No

Cerebrovascular events
Cardiovascular events

Cardiovascular events: ICD9 codes 410 - 414.05,
414.10, 414.11, 414.19, 414.8 - 414.9, 429.79
Cerebrovascular events: ICD9 codes 430.0 - 438.9

Yes

All-cause mortality
Cardiovascular mortality

Cause of death according to ICD-9 codes, for
Cardiovascular mortality: ICD-9 codes 390 - 449

No

All-cause mortality

Death as an adverse event
First occurrence of any of the CV events: MI
(ICD-9 code 410.x), Stroke (ICD-9 codes 433.11,
434.91, 435.x, 438.x), PCI (ICD-9 codes 36.06,
36.07, 0.66; CPT: 92973, 92980, 92995), CABG
(ICD-9 codes 36.1x)
Incidence of MI

Davis et al., 2013

Inpatients and outpatients
treatment files

Cardiovascular events
All-cause mortality

Edwards et al., 2008

Outpatient records, GPRD, UK

Myocardial infarction

Not specified

No

Not specified
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Study

Data source of outcomes

Outcome

Gonzalez-Gay et al.,
2007

Medical records

Cardiovascular events
Cardiovascular mortality

Goodson et al., 2008

Medical records

All-cause mortality
Cardiovascular mortality

Lan et al., 2012

Levesque et al., 2013
Mantel et al., 2014

Meek et al., 2014

Mikuls et al., 2011

Myasoedova et al., 2011

Nadareishvili et al., 2008

Inpatients and outpatients
physician claims in Longitudinal
Health Insurance Database 2005,
Taiwan
Health plan database, Quebec,
Canada
National Patient Register and
Cause of Death Register,
Sweden
Hospital Electronic Registration
System, Medical chart review,
Dutch National Registry of
Death Certificates, The
Netherlands
Veterans Affairs Computerized
Patient Record System (CPRS),
USA
Rochester Epidemiology Project
(REP) medical records linkage
system, USA
Hospitalization records,
physician reports and death
records, confirmed by medical
review or death records.

Definition

Any CV event diagnosed at the hospital in a
patient without previous history of CVD. IHD
included ACS with or without persistent STsegment elevation and chronic CHD.
Cerebrovascular accident included stroke/TIAs
Mortality regardless of cause and cardiovascular
mortality

Excluded patients
with prior or
current CVD

Yes

Not specified

Cerebrovascular event

First occurrence of cerebrovascular event (ICD-9
codes 430.0–438.9)

Yes

Myocardial infarction

Acute MI diagnosis consistent with an ICD-9 code
for MI

No

Acute coronary syndrome

Hospitalization or cause-of-death listing ACS
following RA diagnosis

No

CV events (fatal/non-fatal) included MI, PTCA,
CABG, angina pectoris, acute heart failure, CVA,
death due to cardiac causes and sudden death,
diagnosis was confirmed by a cardiologist

Yes

All-cause mortality

Identified through systematic review of the
Veterans Affairs CPRS

No

Heart failure

Based on the Framingham criteria* for diagnosis
of heart failure

No

Ischemic stroke

Included ICD-9 codes 433.01 - 433.80 and 434 434.91. Excluded intracerebral, subarachnoid,
subdural, and epidural hemorrhages and TIA

No

Cardiovascular event
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Study

Norton et al., 2014
Pope et al., 2001

Data source of outcomes

National Health Service (NHS)
central register, UK
Medical records

Outcome

Definition

Excluded patients
with prior or
current CVD

All-cause mortality

Confirmed by death certificates from NHS register

Not specified

All-cause mortality

Not specified

Prodanowich et al., 2005

Computerized outpatient
medical records

CVD

Suissa et al., 2006

Hospitalization physician
records

Myocardial infarction

Tisseverasinghe et al.,
2009

Hospital records and physician
billing data

CVD

Troelsen et al., 2007

Discharge diagnosis from
hospitalization records

IHD
MI

Death as an adverse event
CVD (ICD-9-CM codes 410.0-410.02, 410.1411.0, 411.89, 413.0-413.9, 414.0-414.9, 429.2),
Cerebrovascular disease (ICD-9-CM codes 433.0433.9, 434-436), Atherosclerosis ( ICD-9-CM
codes 440.0-440.9)
First occurrence of AMI requiring hospitalization
(ICD-9 code 410)
≥1 hospital diagnosis or ≥2 relevant billing codes,
≥8 weeks apart for stroke (ICD-9 code 433.5.x),
IHD (410-1.x, 413.x), PAD (444-5.x) or AMI (≥1
hospitalization)
Verified diagnosis by reviewing clinical charts,
IHD (ICD-10 code I20-I25), MI (ICD-10: I21-I22)

Van den Hoogen et al.,
1996

Medical records

All-cause mortality

Death as an adverse event

Van Halm et al., 2006

Medical records from
rheumatology outpatient clinic,
Amsterdam

CVD

Wasko et al., 2013

National Death Index ,
North America

All-cause mortality

Wolfe and Michaud,
2008
Wolfe et al., 2003

Study questionnaire, hospital
records, physician reports, and
death records
Medical records, death
certificates and the National
Death Index, USA

First CV event. A verified medical history of
coronary (MI, CABG, PTCA, ischemic
abnormality on ECG), cerebral (CVA (confirmed
by neurologist), TIA, Carotid endarterectomy) or
peripheral arterial disease
Death was ascertained by communication with
next of kin or by searching the National Death
Index

Myocardial infarction

MI confirmed by medical or death records review
by independent physician

All-cause mortality

Deaths were confirmed by review of medical
records and death certificates, specific causes of
death were classified using ICD-9 codes

Yes

No

No

Not specified
No

Yes

No

No

Not specified
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Study

Wu et al., 2012

Data source of outcomes

Kaiser Permanente Southern
California EMR, USA

Outcome

Myocardial infarction

Definition

Excluded patients
with prior or
current CVD

First occurrence of fatal or non-fatal MI (ICD-9CM code 410.XX or 412)

Yes

Abbreviations: GPRD: General Practitioner Research Database, CVD: Cardiovascular disease, CHF: Congestive heart failure, CV: Cardiovascular, IHD:
Ischemic heart disease, CHD: Coronary heart disease, ACS: Acute coronary syndrome, TIA: Transient ischemic attack, PTCA: Percutaneous transluminal
coronary angioplasty, CABG: Coronary artery bypass graft, AMI: Acute myocardial infarction, ECG: Electrocardiogram
*Framingham criteria: HF diagnosis requires ≥ 2 of the major criteria [i.e., paroxysmal nocturnal dyspnea or orthopnea, neck vein distention, rales, radiographic cardiomegaly (i.e.,
increasing heart size on chest radiograph), acute pulmonary edema, S3 gallop, increased central venous pressure ≥ 16 cm of water at the right atrium, circulation time ≥ 25 seconds,
hepatojugular reflux, weight loss > 4.5 kg in 5 days in response to treatment of congestive HF)], or the presence of 1 major criterion and ≥ 2 minor criteria (i.e., bilateral ankle
edema, nocturnal cough, dyspnea on ordinary exertion, hepatomegaly, pleural effusion, decrease in vital capacity by 33% from maximal value recorded, and tachycardia rate ≥ 120
beats/min). Minor criteria were counted only if they could not be attributed to another medical condition. Ejection fraction (EF) was determined by echocardiography and classified
as preserved EF (≥ 50%) or reduced EF (< 50%)
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Appendix K. Data for subgroup analysis and meta-regression for primary outcome (cardiovascular events)
Study

Publication
year

Disease

Study design

Study
region

Sample
size

Ajeganova
Davis
Gonzalez-Gay
Meek et al
Prodanowich
Prodanowich
Tisseverasinghe
Van Halm

2013
2013
2007
2014
2005
2005
2009
2006

RA
RA
RA
RA
Psoriasis
RA
DM,PM
RA

Prospective
Prospective
Prospective
Prospective
Retrospective
Retrospective
Case-control
Case-control

Europe
America
Europe
Europe
America
America
America
Europe

741
1047
182
480
7615
6707
411
613

Study

Exposure
source

Excluded
patients
with
CVD

Ajeganova
Davis
Gonzalez-Gay
Meek et al
Prodanowich
Prodanowich
Tisseverasinghe
Van Halm

Database
Database
Medical records
Medical records
Medical records
Medical records
Database
Medical records

yes
no
yes
yes
yes
yes
no
yes

MTX as
timevarying
in
analysis
no
no
no
no
no
no
no
no

Mean
age
(years)
55
63.7
59.7
59
NA
NA
62.4
64.72

% Female

67.5
9.07
72
72.3
5.39
10.15
70
70.35

Adjusted Number Adjusted Adjusted
DMARDs of CV
for CV
for
in
events
risk
smoking
analysis
factors
no
no
no
yes
no
no
yes
no

177
97
39
29
1869
2017
80
72

yes
no
no
yes
yes
yes
yes
yes

yes
no
no
yes
no
no
no
yes

Observation
period (personyears)
9405
3743
NA
1380
NA
NA
0
0

MTX
exposure type
Ever-users
Initiators
Ever-users
Initiators
Ever-users
Ever-users
Ever-users
Ever-users

Adjusted
for CVD

Quality
score

Power
score

no
no
no
no
no
no
yes
no

9
6
8
8
9
9
7
7

0.99
0.88
0.60
0.11
1.00
1.00
0.41
0.08
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Appendix L. Methodological quality of cohort studies according to the Newcastle Ottawa Scale
Study

Representativeness
of exposed cohort
(1 point)

Selection
of nonexposed
cohort
(1 point)

Ascertainment
of exposure
(1 point)

Demonstration
that outcome of
interest was not
present at baseline
(1 point)

Comparability
of cohorts on the
basis of the
design or
analysis
(2 points)

Assessment
of outcome
(1 point)

Adequacy
of follow
up of
cohorts
(1 point)

Total
score
(9 pts)

1

Followup long
enough
for
outcomes
to occur
(1 point)
1

Ajeganova

1

1

1

1

2

1

9

Bozaite-Gluosniene

1

1

1

1

2

1

1

1

9

Chiang

1

1

1

1

1

1

1

1

8

Chin

1

1

1

1

1

1

1

1

8

Choi

1

1

1

0

2

1

1

1

8

Davis

1

1

1

0

1

1

0

1

6

Edwards

1

1

1

0

1

1

1

1

7

Gonzalez-Gay

1

1

1

1

1

1

1

1

8

Goodson

1

1

1

0

2

0

1

1

7

Lan

1

1

1

1

1

1

1

1

8
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Levesque

1

1

1

0

2

1

1

1

8

Meek

1

1

1

1

2

1

0

1

8

Mikuls

1

1

1

1

2

1

1

1

9

Myasoedova

1

1

1

1

2

1

1

1

9

Norton

1

1

1

1

2

1

1

1

9

Prodanowich

1

1

1

1

2

1

1

1

9

Troelsen

1

1

1

0

2

1

1

1

8

Wasko

1

1

1

1

2

1

1

1

9

Wolfe

1

1

1

1

2

1

1

1

9

Wu

1

1

1

1

2

1

1

1

9
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Appendix M. Methodological quality of case-control studies according to the Newcastle Ottawa Scale
Study

Adequate
case definition
(1 point)

Representativeness of
the cases
(1 point)

Selection of
controls
(1 point)

Definition
of controls
(1 point)

Ascertainment
of exposure
(1 point)

Same method
Of
ascertainment
for cases and
controls
(1 point)

Non-Response
rate
(1 point)

Total
score
(9 pts)

1

Comparability
of cases and
controls on the
basis of the
design or
analysis
(2 points)
2

Bernatsky

0

1

1

0

1

1

7

Mantel

0

1

1

1

1

0

1

1

6

Nadareishvili

1

1

1

1

2

0

1

1

8

Suissa

0

1

1

1

2

0

1

1

7

Tisseverasinghe

0

1

1

1

2

0

1

1

7

van Halm

0

1

1

1

2

0

1

1

7

Wolfe and
Michaud.

1

1

1

1

2

0

1

1

8
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Appendix N. Risk of bias assessment of randomized controlled trials (n=3)
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